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EVIDENCE GENERATION FOR EFFECTIVE CHOLERA OUTBREAK 





Cholera is endemic in 69 countries and is responsible for at least 95,000 annual deaths, 
over 900 of which are in Nepal. Studies demonstrate a higher risk of cholera in the 
vicinity of a case. A Comprehensive Targeted Intervention (CTI) was designed and 
deployed adjacent to cholera cases in the Kathmandu Valley with the intent to reduce 
rates among neighbors. This dissertation aims to determine if an immediate, integrated 
response is possible in the Kathmandu Valley while simultaneously generating data to 
support evidence-based interventions to control cholera in the country. 
 
Methods 
Cholera cases were reported from 15 sentinel site hospitals. A single case initiated the 
CTI. Bacterial culture was used for confirmation. The strategy included case 
investigation, water testing, WASH intervention, and health education. Stool samples 
were collected on filter paper for testing genetic relatedness. Case household location 
data was analyzed to determine if a reactive, ring vaccination strategy would have been 
useful in preventing cholera transmission during the outbreak. 
 
Results 
Between June 1 and December 30, 2016, 169 cases of V. cholerae were confirmed by 




household 2 days after the culture result was received. PCR testing confirmed an 
additional 24 cases, and MLVA revealed that all samples were members of a single 
clonal complex. GPS data was available for 69 households and significant clustering of 
cases was seen over space and time. Approximately 85% of cases within a cluster 
occurred more than seven days after the index case. 
 
Conclusion 
RRTs were able to visit case households within 48 hours of confirmation and were 
successful in raising awareness among key stakeholders. The minimal genetic diversity in 
the clinical samples combined with the shape of the epidemic curve indicated a clonal 
outbreak consistent with a common source followed by secondary fecal-oral spread. 
Thus, it seems unlikely that there were multiple introductions of V. cholerae into the 
Kathmandu Valley in 2016. Clustering suggests an opportunity to prevent cholera cases 
though ring vaccination. This analysis has provided useful evidence for implementing 
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1.1.1 The disease 
	
Cholera presents clinically as the rapid onset of acute watery diarrhea, often referred to as 
rice-water stool, and vomiting. Without treatment, the disease can progress rapidly and 
lead to death from severe dehydration in as little as four hours from onset of 
symptoms.[1] Prompt treatment, preferably with oral rehydration solution, can reduce the 
case fatality rate dramatically by limiting the loss of electrolytes, which would otherwise 
lead to lowered blood pressure and shock.[2,3] Severe cases may require intravenous 
fluids to keep up with the body’s rapid loss of fluid. Antibiotics shorten the duration of 
illness and shedding, and should be used for treatment of cases that present to a health 
facility. 
 
1.1.2 The organism 
 
Cholera is caused by ingestion of the Gram-negative, rod-shaped, facultatively anaerobic 
bacterium, Vibrio cholerae.[4] Serotypes of V. cholerae are distinguished from one 
another by the O-antigen of the outer membrane’s lipopolysaccharide (LPS).[2] Out of 
the 200+ serotypes of V. cholerae in existence, epidemic cholera disease is caused by the 
two toxin-producing strains O1 and O139 (non-O1/non-O139 V. cholerae may still be 




largely replaced by the O1 serotype. Serotype O1 is further divided into two biotypes, 
classical and El Tor, which can be differentiated based on their phenotypic properties.[7] 
The classical biotype of the O1 V. cholerae was associated with the earlier pandemics, 
although it has been reported more recently in Mexico as well during a 2012 outbreak in 
Nepal.[8-11] Biotype El Tor has now largely replaced the classical, and is considered the 
cause of the seventh pandemic. Both classical and El Tor biotypes can be further 
characterized into either Inaba or Ogawa serotypes based on the antigens they 
produce.[2] 
 
Two virulence factors, cholera toxin and toxin co-regulated pilus, are responsible for 
cholera disease.[12] Toxin co-regulated pilus plays an integral role in colonization of the 
human intestines by V. cholerae.[13] It has also been shown to play a specific role in 
attachment and bacterial cell protection through biofilm formation within the intestines of 
the human host. Cholera toxin is an enterotoxin that consists of six subunits, one active 
subunit (A) and five binding subunits (B) (Figure 1).[2] Together the B subunits bind to 
receptors in the mucosa of the small intestine, while the A subunit enters the cells and 
activates a process resulting in the discharge of large amounts of fluid into the 
intestine.[14] This excess fluid over-powers the intestines absorption abilities and leads to 
the characteristic watery diarrhea.  
 
1.1.3 The disease burden globally 
	
Cholera has caused seven pandemics since 1817, with the seventh currently on-going.[8] 




cholera has led to an inability to precisely define the global burden. Distinguished from 
other diarrheal diseases by its severity, timely delivery of appropriate therapy is highly 
successful at preventing death.  Despite effective treatment options, out of the 
approximately 1.3 billion people at risk of cholera in endemic countries, an estimated 
2.86 million people contract cholera each year, with around 95,000 deaths.[15] Eight 
countries are estimated to see more than 100,000 cases per year, with the majority of 
these high-burden countries in Africa. The disease disproportionately affects 
disadvantaged groups and recent outbreaks have been a constant reminder of this. The 
2010 outbreak in Haiti has become a seven-year tale with 807,000 cases and over 9,500 
deaths.[16] The most recent (2017) outbreak in war-torn Yemen has already reached 
500,000 cases and 2000 deaths, with estimates of 5000 new infections per day. While 
these outbreaks have been widely discussed among the global health community and 
news media, they are far from the extent of the problem, with at least 14 countries 
reporting deadly outbreaks from June 2015 to June 2016 alone.[17] 
 
1.1.4 The disease burden in South Asia 
	
A total of 51 countries are classified as endemic for cholera according to a 2015 article on 
the global burden of the disease.[15] Six of these countries are in South East Asia, 
including Nepal and its neighbors, China and India. Cholera is considered to have been 
born in this region, with the first written description of the disease in India between 500-
400 BC, and the first of the seven pandemics beginning in the Ganges river delta of India 
in 1816.[18,19] In fact, all of the pandemics began in this region, with only the current 




818,000 cases of cholera annually, with around 24,500 deaths.[15] However, these 
estimates are a result of statistical modeling as most cholera cases in this region, and 
around the world, go unreported. While this is in part a surveillance issue, there is often a 
large economic disincentive to report as well particularly in regard to trade and tourism. 
The high number of cases from this region is likely attributable to their high number of 
risk factors for the disease, including high population density, extreme poverty, lack of 
development, and environmental factors such as monsoon flooding.[20]    
 
1.2 Nepal 
1.2.1 The country 
	
Nepal is a land-locked country, bordered by China to the north and India to the west, 
south, and east. The country has a population of approximately 28.5 million and consists 
of five development regions, the far-western, mid-western, western, central, and eastern 
regions (Figure 2).[21] These regions are divided into 14 administrative zones, 
comprised of 75 districts; these are further broken down into village development 
committees (rural areas) and municipalities (urban areas), which are made up of wards. 
There are three distinct ecological zones: the mountains, the hills, and the terai. A small 
minority of the population resides in the mountains (around 7%), while the rest are split 
between the hills and terai.[22] Kathmandu Valley lies within the hill region, and is the 





1.2.2 The health system 
	
Nepal’s Department of Health Services (DoHS), within the Ministry of Health, is divided 
into seven divisions (Planning and Foreign Aid, Family Health, Child Health, 
Epidemiology and Disease Control, Logistic Management, Human Manpower 
Institutional Development, and Leprosy Control) and five centers (Health Training, 
Health Education Information and Communication, Tuberculosis, Center for AIDS and 
STD Control, and National Public Health Laboratory) organized as shown in Figure 3. 
At the regional level there is the Regional Health Services Directorate (Hospitals, 
Training Center, Health Laboratory, Medical Store, and Tuberculosis Center). The Zonal 
Hospitals report to their respective Regional Health Services and oversee the district level 
services (District Health Office, District Hospital, and District Public Health Office). The 
Primary Health Centers within each district directs the Health Posts (and Sub-Health 
Posts). Community level health in Nepal consists of Female Community Health 
Volunteers (FCHVs), Trained Birth Attendants, Primary Healthcare Outreach, and the 
Expanded Program on Immunization Outreach.[23] 
 
Cholera surveillance and reporting in Nepal has two avenues: reported cases, and cases 
that are laboratory confirmed (Figure 4). In most cases, a patient reporting to a local 
health post with five or more episodes of watery diarrhea will be reported as a cholera 
case to the district public health office (DPHO) and enter into the country’s Health 
Management Information System (HMIS). Alternatively, that patient may report to a 
hospital in their district that is able and/or required to confirm the suspected cholera case 




Control Division (EDCD), as well as the National Public Health Laboratory (NPHL). In 
1998, a program of laboratory-based Antimicrobial Resistance Surveillance (AMR) 
began enlisting hospitals with adequate capacity to test for resistance in certain isolated 
pathogens. There is virtually no communication between these two avenues for cholera-
case reporting, which leads to contradictory descriptions of the true burden of disease. 
 
1.2.3 The history of cholera in Nepal 
	
Epidemics of cholera in Nepal can be traced back to at least 1823, when the disease was 
commonly attributed to “the influence of Saturn and other planets” and the “evil 
eye.”[24] In 1885, Gimlette described a large outbreak, beginning in May in the 
Kathmandu Valley, with between 9 and 10 thousand deaths.[24] Outbreaks continued to 
occur yearly in the Valley and in 1958 the first bacteriologically confirmed epidemic was 
reported in Kathmandu to the World Health Organization Regional Office for South-East 
Asia. In 1961 cholera was first described as endemic in Nepal.[25] By 1991, cholera 
could be found in all five development regions in the country and was a routine 
contributor to the “annual monsoon-season gastroenteritis outbreak.”[26] A yearlong 
study elaborated on the seasonality of cholera in the country, detecting no cases from 
December to May, with the highest caseload in August.[27] At least one study has 
reported an outbreak outside of the typical season, in October-November.[28] However, it 
is widely accepted that the rainy summer months in Nepal constitute the cholera season. 
 
There have been a multitude of more recent published reports of outbreaks around the 




description of a Nepalese strain, V. cholerae O1 biotype El Tor serotype Ogawa.[29,30] 
A single case of V. cholerae O139 was reported during a 1997 outbreak in Kathmandu, 
although a Nepalese O139 strain without direct connection to an outbreak had been 
reported previously.[31,32]  In a 1996 paper on diarrheal disease in Nepal, two additional 
serotypes, Inaba and Hikojima, were identified in children under 14.[27] These serotypes 
were reported again in 2007 based on data from Nepal’s National Public Health 
Laboratory.[33] Inaba serotype appeared intermittently as a small proportion of isolates 
for many years, but has not been detected since 2007.[34] The 2012 Kathmandu outbreak 
was the first report of the classical biotype in Nepal, with no instance of the El Tor 
biotype.[9,35] Overall, El Tor Ogawa has been the most commonly published biotype in 
the country. 
 
A brief report in 1996 was the first to discuss antimicrobial resistance and noted reduced 
sensitivity to nalidixic acid, co-trimoxazol, ampicillin, and cephalexin.[36] Two years 
later the Ministry of Health in Nepal, in collaboration with the International Centre for 
Diarrhoeal Disease Research, Bangladesh, established an AMR Surveillance program. 
This program began as nine laboratories (now expanded to 22), reporting on five 
pathogens, one of which was V. cholerae.[37] In 2004, cholera isolated during an 
outbreak in Kavre district was found to be completely resistant to co-trimoxazole, but 
sensitive to all other antibiotics tested.[38] Another study conducted that year found 
resistance to nalidixic acid as well.[39] By 2008, an outbreak in Kathmandu (and later in 
Saptari and Jajarkot) produced isolates that were 100% resistant to furazolidone in 




resistance pattern as early as 2005.[44] Resistance to trimethoprim, sulfamathoxazole, 
and decreased susceptibility to ciprofloxacin was reported in 2010 and to streptomycin in 
2012.[45,46] Multi-drug resistant V. cholerae has also been identified in Kathmandu’s 
sewer system.[47] The variation in resistance profile results in the need for continuous 
monitoring to ensure effective drugs are being used when necessary.[46] 
 
The vast majority of published outbreaks of cholera in Nepal are in Kathmandu. While it 
could be argued that Kathmandu simply has the greatest capacity for case detection, they 
also have dealt with an influx of people from rural areas, impacting the city’s ability to 
provide safe drinking water and proper sanitation.[34] In the aftermath of the April and 
May 2015 earthquakes in Nepal, access to a water supply already considered unsafe 
decreased dramatically.[46,48,49] This, along with the damage sustained by 90% of the 
health facilities in the highly affected rural areas, has increased the country’s risk for an 
outbreak of cholera.[49,50] Although Nepal made it through its first post-earthquake 
monsoon season with no increased incidence of cholera, the danger has not yet 
passed.[51] 
 
1.3 Tools in Cholera Diagnosis and Prevention 
1.3.1 Rapid diagnostic test   
	
In the field where laboratory capacity is limited, rapid diagnostic tests (RDT) can be used 
to diagnose O1 and O139 V. cholerae.[52] The dipstick test uses monoclonal antibodies 




of the organism, similar to a pregnancy test.[53,54] The dipstick can be inserted directly 
into a stool sample, which has been mixed into a small amount of buffer solution, and 
results are visible in 15 minutes. Colored bands indicate whether the sample is positive 
for O1, O139, or neither, in which only the control line is visible. In comparison to 
culture, the rapid diagnostic test is about 71-77% specific in the field.[55-58] Sensitivity 
is much greater, documented at around 90%. Specificity is consistently higher, over 90%, 
with sample enrichment.[53,56,57,59,60] In the enhanced dipstick method, specimens are 
enriched in a selective media, alkaline peptone water (APW), for six hours prior to testing 
the broth with the dipstick.[59,60] 
 
One potential limitation to the use of RDTs is their use in conjunction with the oral 
cholera vaccine. The vaccine can be used in a reactive manner during an outbreak to 
prevent the spread of disease. Since the cholera vaccines used today contain killed, whole 
cells of V. cholerae, RDTs may produce positive results from the stool of vaccinated 
individuals who are free of cholera disease. While this phenomenon has been 
documented, the period of risk for false positives has not been studied extensively.[61]  
 
1.3.2 Filter Paper Specimen Storage 
	
Cholera occurs most often in countries with limited resources and laboratory capacity, 
especially in rural areas. Many cases go undiagnosed or unconfirmed due to a lack of 
cold chain or media necessary to transfer samples to a better-equipped reference 
laboratory for processing. Debes et al. showed that bacterial DNA from stool samples 




need for resource-demanding storage and making transfer to a reference laboratory for 
molecular processing much simpler.[62] In a country like Nepal where little capacity for 
advanced methods exists outside of the capitol city, this method could be a huge step 
towards better surveillance and confirmation of the national cholera burden. 
 
1.3.3 Molecular Tools  
	
The typical standard for confirming the presence of cholera in the stool of a patient in 
countries like Nepal is bacterial culture on selective media. However, this method is not 
100% sensitive and sensitivity decreases if there are delays in transport of the specimen 
to the microbiological laboratory, as occurs commonly from remote areas of Nepal. For 
laboratories with capacity for molecular testing, confirmation by polymerase chain 
reaction (PCR) is a more reliable gold standard. This method utilizes a series of multiplex 
(multiple primer) PCR amplifications to determine the presence of cholera DNA in the 
stool. These primers are designed in sequence to target Vibrio species, distinguish 
toxigenic from non-toxigenic cholerae, and finally identify the serogroup. Since only 
DNA is required, the cholera organisms do not need to be alive for this detection method, 
making it an ideal alternative to culture when stool samples cannot be obtained for 
processing in a timely manner.   
 
To further distinguish the V. cholerae strains identified, a method known as multi-locus 
variable-number tandem-repeat analysis (MLVA) is used. MLVA works by identifying 
short DNA sequences that repeat in tandem at specific, pre-defined loci specific to the 




compared with a reference library to differentiate the strains. This method is a 
particularly useful epidemiologic tool in outbreak situations to determine how related 
strains are, and how that may change over time and space.  
 
1.3.4 Oral Cholera Vaccine 
	
Cholera vaccines have been used in humans as far back as 1885.[64] Up until the 1970’s 
attenuated cholera vaccines were injected, or parenteral, until a study showed that the 
vaccines performed poorly, with only 50% protection for less than six months.[65,66] In 
1985 the first oral vaccine went to trial, but it was not until 2010 that oral cholera 
vaccines (OCV) were recommended by the World Health Organization (WHO) for their 
safe and easy administration, higher acceptability, and attention to the idea of mucosal 
immunity.   
 
There are currently four licensed killed vaccines for cholera prevention: (i) Shanchol, 
which contains killed whole cells of V. cholerae serogroups O1 and O139; (ii) Dukoral, 
containing killed whole cells of V. cholerae serogroup O1 and recombinant B-subunit of 
cholera toxin; (iii) mORC-Vax, which is very similar to Shanchol; and (iv) Euvichol, 
killed whole cells of V. cholerae O1 (Classical and E1 Tor biotypes) and V. cholerae 
O139.[67] Dukoral, Shanchol, and Euvichol were prequalified by the World Health 
Organization in 2001, 2011, and 2015, respectively. 
 
Shanchol has been shown to confer 58% cumulative protection with two doses to 




horizon to observe the benefits of vaccination. Therefore, vaccine can confidently be 
given to any at-risk population, without the need to pinpoint exactly when an outbreak 
will occur. The vaccine also induces significant herd protection, but more research needs 
to be done into how to maximize this benefit. While no studies have been published with 
one-dose efficacy for longer than 6 months as the primary endpoint, a one-dose regimen 
does provide significant short-term protection.[71,72] 
 
More than 11.5 million doses of OCV have been administered worldwide.[73,74] In 
2013, WHO established a stockpile of OCV and issued the following statement: “Given 
the availability of two oral cholera vaccines and data on their efficacy, field effectiveness, 
feasibility and acceptance in cholera-affected populations, immunization with these 
vaccines should be used in conjunction with other prevention and control strategies in 
areas where the disease is endemic and should be considered in areas at risk for 
outbreaks.” Requests exceeded supply for the first time in 2015, and have been doubling 
every year since 2013.[75] This increase may be due to the more visible and accessible 
supply, but could also be the result of increasing amounts of information in the literature 
on effectiveness and feasible delivery strategies.[76] 
 
OCV is typically delivered through campaigns, rather than through a routine 
immunization program. Rather than vaccinating entire countries through national 
campaigns, it is given in specific areas that are deemed to be at highest risk. There are 
three general times in which OCV will be used, in an endemic area for prevention, to 




that is already underway. While it has been the standard approach in all three scenarios to 
identify an area of high risk, such as a refugee camp or municipality, and vaccinate all 
members with two doses of vaccine, there has recently been buzz in the field surrounding 
a ring vaccination approach to outbreak response.[77,78] This approach builds upon the 
idea that those at highest risk of disease are individuals that live in close proximity to a 
case. This is another method of determining a high-risk area, which could be ideal in 
settings where little is known about the epidemiology of cholera or when vaccine is in 
short supply. 
 
OCV is not intended to be the sole intervention to prevent cholera mortality. Where it 
was once considered competitive, it is now considered important that OCV be integrated 
with other interventions, such as improved case management, water, sanitation and 
hygiene (WASH), and health communications.[76,79] Where and when to use OCV 
depends strongly upon surveillance, which is generally lacking in most cholera endemic 
areas.[49] Combining with other measures ensures some level of protection for the 
population, specifically for a reactive strategy where intensive WASH could provide 
protection during the 4 – 7 days it will take for OCV to become protective.  
 
1.3.4 OCV in Nepal 
	
A cholera outbreak in the Central Region of Nepal, along the border of Rautahat and 
Makawanpur districts, began on April 30, 2014. The affected area was isolated, rural, and 
suffered from poor water and sanitation. When a social mobilization campaign to inform 




failed, the EDCD of the DoHS in Nepal made the decision to conduct an immunization 
campaign in the region. A plan for conducting the campaign, and a request for vaccine 
was sent to the Global Cholera Vaccine Stockpile Unit at the WHO. The application was 
successful and 36,000 doses of OCV (Shanchol) were granted to the country. Two rounds 
of vaccination took place between September 12-13, 2014 and September 26-27, 2014. 
Out of the 36,000 doses procured, 16,000 were used during the campaign, which resulted 
in an administrative coverage rate of 72%. 
 
In the aftermath of the April and May 2014 earthquakes, a second vaccination campaign 
was carried out in the Central Region in the district of Newakot. Unlike the previous 
reactive campaign, this campaign was preemptive, as Newakot was highly affected by the 
earthquake. Camps of internally displaced persons, as well as villages at high risk of 
outbreak were targeted. Two doses of vaccine were offered, with the first round of 
immunizations from August 8-12, 2015 and the second round from August 30th – 
September 3, 2015. The remainder of the country’s OCV stockpile was used during this 
campaign (20,000 doses). The EDCD estimates an administrative coverage rate of 95%. 
 
Banke district in Western Nepal has consistently reported cases of cholera for the past 
five years and, combined with a high proportion of the population that lacks access to 
safe water, sanitation, hygiene and health services, it is an area at high risk for continued 
outbreaks. Due to a generous donation from the Rotary Global Grant Fund, a total of 
55,000 doses of OCV were given for a vaccination campaign in three areas of Banke 




municipality, with a total population of 0.49 million people. The total selected population 
for the targeted OCV campaign was nearly 27,000 individuals residing in the VDCs 
Sonapur and Udarapur, and ward five of Nepalgunj municipality. An estimated 24,000 
people were vaccinated with two doses during this campaign and the administrative two-
dose coverage was estimated to be over 90%. 
 
1.4  Rationale 
	
The likelihood of a quick recovery from the earthquake-imposed damage incurred in 
Nepal is unlikely, largely due to the extent of the loss of infrastructure.[80] Between 
660,000 and 1.3 million people suffered damage to their primary water sources, and 
sanitation support is needed for 850,000 to 1.7 million. This is on top of the 945 heath 
facilities that have either partially or totally collapsed. While the country escaped its first 
monsoon season with reports of only a small outbreak in the Kathmandu Valley, the risk 
of cholera remains great in the Valley. With little reconstruction, the situation remains 
bleak regarding water and sanitation in the most highly affected districts. This, combined 
with a lowered guard and a lack of awareness of risks due to the lack of a large outbreak 
last season, could lead to a larger outbreak and a delayed response. 
 
A review of the literature on cholera in Nepal revealed that while the disease is endemic 
and occurs nearly every year in the Kathmandu Valley, exactly where it will occur is 
difficult to predict. This is partially due to a fragmented surveillance system, with no 
solid body of evidence to support advanced preparation. As a foundation for this 




2014 was performed in an effort to shed light on the state of the surveillance system, how 
it functions in the country, and paint a clearer picture of which areas of the country are at 
greatest risk of outbreaks, historically. Data was collected on both reported and 
confirmed cholera cases. For reported cases, case counts and line lists were collected 
from district public health offices around the country representing all five development 
regions and three ecological zones. A meeting of the Steering Committee for Enteric 
Diseases was held on April 15th, 2015 where it was decided that data would be collected 
from 25 districts on the basis of frequent outbreaks and high incidence of severe diarrhea 
cases as reported in the DoHS Annual Reports beginning in 2011. Confirmed case counts 
were collected from 17 of the country’s 18 AMR sites, which included both public and 
private institutions, as well as two referral hospitals. 
 
Over a four-month period, study data was collected retrospectively from 22 districts and 
12 hospitals. A total of 26,947 cases of cholera were reported from these 22 districts from 
2005 to 2014 with an overall case fatality rate (CFR) of 1.2%. Seven of 22 districts 
reported no cases during that ten year period, six of which (Taplejung, Illam, Jhapa, 
Sunsari, Okhaldhunga, Bhaktapur, and Darchula) had reported cholera cases in the DoHS 
annual reports.[81]  
 
Information was collected on 2,140 inpatient cases with severe diarrhea from 13 of the 19 
hospitals the study planned to visit. Out of these cases, 628 had a provisional diagnosis of 
cholera and only four had cholera listed as the final diagnosis. None of the cases were 





Figure 5 shows the total number of cases and deaths reported per year from all 22 
districts combined, in addition to the CFR. No data was available for 2005, and no cases 
were reported in 2006 or 2007. While 2009 and 2014 both had large numbers of cases, it 
is important to note that in 2014 over 96% of the cases were from a single district, 
Rukum.  
 
The location of cases varied from year to year, but the majority of cases were reported in 
the Mid-western region of the country. It is highly likely that these cases are only the tip 
of the iceberg. In a retrospective study on the incidence of cholera in Uganda, it was 
assumed that the cases detected were only 25% of the true total, as most diarrheal cases 
(in Uganda as well as Nepal) are treated at home.[82] The significant amount of data 
missing at the hospital and district level may reveal that the surveillance data in Nepal is 
largely incomplete and further masks the true cholera burden. If this is the case, the same 
could likely be concluded about cholera mortality, as deaths that occur outside the 
hospitals/health posts would go unrecorded.   
 
The WHO recommends confirmation of the clinical diagnosis in a small fraction of cases 
at the beginning of an outbreak. However, there was a lack of lab confirmed cholera 
cases at the 16 AMR sites visited for data collection even in districts with cholera cases 
reported. It seems that while the AMR sites have the laboratory capacity to confirm 





This review assisted in identifying the limitations of the cholera surveillance system, but 
leaves the question of how best to approach cholera surveillance and prevention in light 
of those weaknesses. As outlined above, the global supply of OCV is incredibly limited 
as compared to the global at-risk population. While mass vaccination of the at-risk 
population seems reasonable given the increased risk post-earthquake, this population in 
the country is much greater than the available vaccine. By designing an intervention that 
focuses on halting an outbreak early rather than preventing one entirely, it may be 
possible to avoid more morbidity and mortality. A study in Matlab, Bangladesh showed 
that those living closest to a case (within 50 meters) had 36 times the chance of becoming 
infected with cholera than those living in other areas of the community.[78] This risk was 
highest during the first three days after the index case was identified. A reactive 
vaccination strategy, when partnered with other key cholera prevention measures, forms 
the backbone of a comprehensive-targeted intervention (CTI) approach to cholera control 
and has the potential to halt the spread of cases if deployed rapidly. Founded on a 
strengthened hospital-based surveillance system, the CTI approach combines pointed 
health behavior messaging with traditional WASH interventions and a single-dose (87% 
short-term effectiveness) OCV campaign to prevent the spread of cholera once it 
strikes.[71] Demonstrating feasibility and effectiveness of such a strategy would provide 







1.5 Specific Aims 
	
The overall goal of this dissertation was to assess the feasibility of a comprehensive, 
targeted response to a cholera outbreak in Kathmandu Valley, Nepal in a way that 
simultaneously generates data that can be used to better understand the epidemiology of 
the disease.  
 
1.5.1 Specific Aim 1 
 
Evaluate the feasibility of a comprehensive, targeted intervention that employs a reactive 
ring approach for preventing the spread of cholera in Kathmandu Valley, Nepal 
 
1.5.2 Specific Aim 2 
	
Differentiate clinical cholera isolates from an outbreak in Kathmandu, Nepal using multi-
locus variable-number tandem repeat analysis to explain the genetic epidemiology of the 
disease in the Valley 
 
1.5.3 Specific Aim 3 
	
Determine the spatiotemporal relationship of cholera cases during the 2016 outbreak in 













Figure 1.1 Structure of the cholera toxin. Panel A shows the A subunit in red and the B 
subunit in blue. Each monomer of the B subunit can be seen in a different color in Panel 













Figure 1.2 Development regions and ecological zones of Nepal. The study area is 
located in the hills of the central region. 
22 
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Figure 1.4 Framework for cholera surveillance and reporting in Nepal. Solid arrows 
indicate the flow of information from the health facilities to the national level. Dashed 
arrows represent reporting from the government to the periphery on surveillance efforts. 
Note that there is no overlap between the two avenues, resulting in conflicting reports of 







Figure 1.5 Annual number of cholera cases and deaths from 2005 to 2014. Cases 
were reported from 22 districts as part of a retrospective study of cholera in Nepal. 
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2.1 Paper One Abstract 
2.1.1 Background 
	
Cholera is endemic in Nepal and the vast majority of published outbreaks of cholera in 
the country have been in Kathmandu.	Studies have demonstrated a much higher risk of 
cholera in the immediate area around a case and that this increased risk persists for about 
2 to 3 weeks. A Comprehensive Targeted Intervention (CTI) was designed and deployed 
in the neighborhoods of cholera cases in the Kathmandu Valley during 2016 with the 
intent to reduce rates among neighbors of the case. This was a feasibility study to 
determine if clinical centers, laboratories and field teams were able to cooperate and 
coordinate a response within 48 hours of hospital admission. We hypothesized that this 




Daily line listings were requested from the 12 participating hospitals, and a single case 
initiated the CTI. A standard case definition was used: Acute watery diarrhea, with or 
without vomiting, in a patient aged one year or more.	Rapid diagnostic tests and bacterial 
culture were used for confirmation. The strategy included hospital and household 
investigation of cases, water testing, WASH intervention, and health education. A single-
dose of oral cholera vaccine using a reactive ring strategy was included in the plan, but 
vaccine could not be obtained in time for the summer 2016 outbreak. An intervention 






Between June 1 and December 30, 2016, 169 cases of V. cholerae O1 were confirmed by 
bacterial culture. Average time to result of hospital culture was 2.4 days. On average, the 
CTI Rapid Response Team (RRT) was able to visit the household 2 days after the culture 
result was received from the hospital. 90.4% of household water samples were found 
unsuitable for drinking and 3 sources were positive for cholera. Coverage of WASH and 
health behavior messaging campaigns was 30.2% in the target areas. Recipients were 2.3 




This attempt at implementing CTI was successful in raising awareness and engaging 
stakeholders in both government and private sectors. While the RRT were able to 
investigate cases at the household within 48 hours of a positive culture result, the study 
identified several constraints that limited a truly rapid response.  Using the information 
from this first year, we identified pathways that will be useful for future implementation 















Cholera, caused by ingestion of the bacterium Vibrio cholerae, presents clinically as the 
rapid onset of acute watery diarrhea and vomiting. Without treatment, the disease can 
progress rapidly and lead to death from severe dehydration in as little as four hours from 
onset of symptoms.[1] Prompt treatment can reduce the case fatality rate dramatically by 
replacing lost fluid and electrolytes, which would otherwise lead to lowered blood 
pressure and shock.[2,3] A study in Matlab, Bangladesh showed that those living closest 
to a case (within 50 meters) had 36-fold higher chance of becoming infected with cholera 
than those living in other areas of the community.[78] This risk was highest during the 
first three days after the index case was identified. Similar results were seen in Kolkata, 
India, where an increased risk for cholera was seen within 25 to 50m of a case and 
persisted for a month.[77] These observations highlight that rapid detection of cholera 
cases is needed in order to react and prevent the spread of disease. 
 
Cholera is endemic in Nepal, with an estimated 30,000 cases and 911 deaths per year 
during the monsoon months of May through September.[15] While the disease occurs 
nearly every year in the Kathmandu Valley, exactly where it will occur is difficult to 
predict. This is partially due to a fragmented surveillance system, with no solid body of 
evidence to support advanced preparation. 
 
Despite much recent progress, the global supply of oral cholera vaccine (OCV) is 
incredibly limited as compared to the global at-risk population.[76] By designing an 




it may be possible to limit the transmission from index cases and reduce overall rates of 
disease by targeting the high-risk groups. A reactive vaccination strategy, when partnered 
with other important cholera prevention measures, forms the backbone of a 
comprehensive-targeted intervention (CTI) approach to cholera control and has the 
potential to halt the spread of cases if deployed rapidly. Founded on a strengthened 
surveillance system, the CTI approach combines pointed health behavior messaging with 
traditional water, sanitation and hygiene (WASH) interventions and a single-dose OCV 
campaign (estimated to have a short term effectiveness of 87%) to prevent the spread of 
cholera once it strikes.[71] Despite much recent progress, the global supply of OCV is 
incredibly limited as compared to the global at-risk population.[76] By designing an 
intervention that focuses on halting an outbreak early rather than preventing one entirely, 
it may be possible to reduce morbidity and mortality. Demonstrating feasibility and 
effectiveness of such a strategy would provide a new cholera control method for Nepal 
and other countries in post-disaster and high-risk situations. 
 
2.2.1 Study Objective and Rationale 
	
The Epidemiology and Disease Control Division (EDCD) of the Department of Health 
Services (DoHS) in Nepal adopted a CTI approach to cholera control for the 2016 
monsoon season, expanding the role of the country’s existing rapid response team (RRT) 
network. This is a feasibility analysis of that response. We hypothesized that a CTI 
strategy for controlling cholera in Kathmandu Valley would facilitate a cooperative and 
unifying method for cholera control and could potentially reduce transmission in this 




faces many challenges – poor disease surveillance, limited laboratory capacity, and loss 
of health infrastructure to name a few.[49] The main challenge lies in engaging 
stakeholders involved in cross-sectoral activities to work together and achieve a fast and 
effective response to a cholera outbreak once it has started.  
 
2.3 Methods 
This was designed as a feasibility study to determine if clinical centers, laboratories and 
field teams were able to cooperate in a manner that resulted in a CTI approach within 48 
hours of a case reporting for treatment. Detailed records on timeliness were kept for each 
phase of the response and these were reviewed with the goal of answering specific 
questions regarding time to response (Table 1).  
 
2.3.1 Intervention Summary  
Enhanced hospital-based surveillance for cholera cases took place at 15 sites throughout 
the Kathmandu Valley, consisting of Kathmandu, Lalitpur, and Bhaktapur districts. 
Sentinel sites identified patients suspected to have cholera using a standard case 
definition: Acute watery diarrhea (AWD), with or without vomiting, in a patient aged 
one-year or more. Daily line listings of AWD cases were requested from each hospital, 
including zero-reporting, and a single suspected case of cholera initiated the CTI cascade. 
When such a patient was identified, the hospital was expected to perform a rapid 
diagnostic test (RDT) or culture for cholera and sent a stool specimen to the National 
Public Health Laboratory (NPHL), for culture confirmation and serotyping. Within the 




Once notified, the RRT was expected to travel to the neighborhood of the index case the 
same day (or the next day if necessary) to initiate the CTI intervention.  
 
The complete CTI intervention included (Figure 1):  
1. Hospital and household investigations of each case 
2. An intensive water, sanitation, and hygiene (WASH) intervention to the case 
household and the first degree neighbors 
3. Community-level WASH activities and health education messaging in the 
neighborhood surrounding the case in order to encourage safe water, safe food 
and hand-washing 
4. Water testing for V. cholerae at each index household 
5. An OCV campaign in the neighborhood of the index case, given within a 100m 
ring, to approximately 1000 persons, using a single-dose strategy  
 
2.3.2 Case Investigation 
Patients meeting the case-definition for cholera were expected to have their clinical 
information recorded at the hospital by the RRT in what was termed the hospital 
investigation. Data collected here focused solely on the index case and included a 
summary of demographic characteristics, signs and symptoms, and approximate address. 
This data was aggregated and used to generate daily situation reports for the ministry and 




The RRT was then to be deployed to the home of the index case within 24 hours to 
conduct the household investigation. GIS locations of the homes were recorded to map 
the geographic distribution of the outbreak. If a family did not consent to a home-visit, or 
if the RRT was unable to contact the family, the approximate location of the household 
was mapped. Household investigation data included information on water sources, water 
treatment, history of diarrhea within the household over the last two weeks, history of 
food consumption and travel, and sanitation and hygiene behaviors of the entire 
household. 
 
2.3.3 WASH Intervention 
The family of the index case and their immediate neighbors were then to be targeted for a 
door-to-door awareness campaign aimed at educating the high-risk groups on the risk of 
cholera transmission and methods for prevention. These campaigns were primarily 
targeting households, however, schools and food vendors were included if they were in 
the target area. The RRT was expected to visit the households within 48 hours of the 
initial index case in that area. Households were to receive orientation and equipment for 
point-of-use water treatment. This included chlorine tablets, basic buckets for water 
storage and hand washing, and soap. They were also expected to receive education, both 
verbal communication and a flyer for future reference, on hand washing at critical times, 





2.3.4 Health Education Intervention 
Female community health volunteers (FCHVs) were also expected to deliver messages to 
the broader community surrounding the index case on various cholera prevention 
strategies. These messages included boiling, filtering, or treating water with chlorine, 
basic hygienic food preparation, parasite prevention methods, and the importance of 
vitamin A supplementation. Messages were to be delivered in a variety of ways in order 
to maximize coverage. Booths were set up in community areas with high foot traffic and 
FCHVs handed out flyers and answered questions. Awareness rallies were held with 
banners displaying prevention methods. Presentations were given at meetings of 
community groups and schools, and radio messaging was projected from a vehicle 
(miking).  
 
2.3.5 Water Sampling 
Surface water samples (3 liters each) were collected from primary and secondary 
drinking water sources for the index case households, filtered through sterile gauze, and 
incubated in selective media (alkaline peptone water) for 24 hours.[84] The NPHL then 
performed culture analysis to preserve any V. cholerae isolates on thiosulfate citrate bile 
salt sucrose agar. 
 
RRTs and FCHVs used a coliform presence/absence (H2S) test kit, as a visual 
demonstration of water unfit for drinking.[85] This version of the test was developed by 
the local Environment and Public Health Organization and is a simple, low-cost method 




line, incubated at room temperature for 24-48 hours and is observed for a color change 
indicative of contamination. These vials were used at households, schools, and in the 
community on all water sources.  
 
The NPHL also performed a quantitative test for coliforms, the Idexx colilert-18 test.[86] 
When coliforms metabolize colilert-18’s ortho-nitrophenyl-beta-D-galactopyranoside, the 
sample turns yellow. Yellow wells were then counted and coliforms per 100mL were 
determined via a most probable number table provided with the test kit. 
 
Total chorine tests were also performed on household water sources as well as for tankers 
supplying water to the community. These tests used the low-cost chemical orthotolidine, 
which turns yellow in the presence of chlorine.[87] Results of testing at the community 
level were shared with that community as well as solutions to any water quality issues 
identified. 
 
2.3.6 OCV Intervention 
A single dose of OCV was to be administered by the RRT using a door-to-door, reactive 
ring strategy in the neighborhood of the index case. The ring size to be used was chosen 
by the EDCD to be approximately 100 meters based on knowledge of population density 
in the Kathmandu Valley and a goal of vaccinating approximately 1000 people per ring. 
The RRT was expected to deliver vaccine to men and non-pregnant women greater than 




health facility. Unfortunately, vaccine could not be obtained in time for the summer 2016 
outbreak.  
2.3.7 Follow up 
As part of the post-CTI program monitoring and evaluation, a survey was conducted in 
each of the areas targeted for community-level WASH intervention. A field team visited 
each of the intervention areas and administered a simple questionnaire to households 
using a multistage cluster sampling method. A total of 400 households were targeted for 
the survey. First-stage clusters were the targeted wards, and the number of households 
sampled was proportionate to population size. For first-stage clusters larger than 20 
households, an additional cluster was added within that ward, resulting in 30 total 
clusters. Second-stage clusters were chosen according to the World Health Organization 
vaccine coverage survey guidelines.[88] The survey asked residents if their home was 
visited by a WASH volunteer, if they heard the health messaging in their neighborhood, 
if they received specific information on health promotion from the volunteers, received 
water purification materials, etc. It also included an assessment of their ability to answer 
basic hygiene promotion, water purification, and cholera prevention questions. 
 
2.3.8 Analysis 
The number of cases over the course of the outbreak was graphed and cases were mapped 
by location of household using ArcGIS. Basic demographic characteristics of AWD 
cases, cholera cases, and survey respondents were described. Feasibility was measured 
through indicators of timeliness and quality of implementation (Table 1). Survey data 




stratified by whether or not a WASH intervention was received in that household and 
comparisons were tested for significance via chi-square test. Statistical analyses were 
performed using Stata version 12 (StataCorp, LLC, College Station, Texas, USA). 
 
2.3.9 Ethical approval 
Institutional Review Board (IRB) approval was obtained from the Johns Hopkins 
University IRB and the Nepal Health Research Counsel for the use of de-identified data 
collected during the campaign. 
 
2.4 Results 
A total of 2,207 cases of AWD were reported from the sentinel sites to the EDCD 
between June and November 2016 (Table 2). Of those AWD cases, 239 were classified 
as suspected cholera. In total, 169 cases were culture confirmed as V. cholerae O1 Ogawa 
(Table 2; Figure 2). Rapid diagnostic test results were compared to bacterial culture and 
resulted in a sensitivity and specificity of 90% and 70%, respectively. No cases of the 
serotype Inaba were seen. Male-female ratio was similar between both patient groups. 
Cholera cases were significantly younger than AWD cases by approximately ten years 
(p<0.001). The majority of cases were detected from the Kathmandu Valley. The 
geographic distribution of cholera cases can be seen in Figure 3. Over 70% of cases were 





An evaluation of the speed with which the CTI was implemented can be seen in Figure 
4. The average time from hospital admission to hospital laboratory results was 3.1 days 
(sd: 1.8; range 1 to 8 days). Average time from hospital admission to NPHL culture 
confirmation was 5.2 days (sd: 1.9; range 1 to 12 days). RRTs interviewed a total of 132 
of confirmed cases in the hospital (78% of total cases) and out of those cases 92 
household investigations were performed (54% of total cases). On average the RRT was 
able to visit the household 1.7 days after the culture result was received from the hospital 
(sd: 1.4; range: 0 to 6 days). It took an average of 4.0 days from hospital admission to 
household investigation (sd: 2.3; range 1 to 17).  
 
Water samples were collected from all case households that were investigated and 90.7% 
(117/129) of those household water samples were found unsuitable for drinking based on 
coliform count (greater than 1 coliform per 100 ml). Three household water sources were 
positive for V. cholerae O1 Ogawa. Only 8.5% of drinking water samples tested had 
detectable levels of chlorine (10/118). 
 
WASH and health behavior messaging campaigns were conducted in 18 areas of Lalitpur 
and Kathmandu districts. On average these campaigns happened 9 days after the initial 
case in that area was admitted to the hospital (sd: 6.8; range: 0 to 37 days). A total of 394 
households were surveyed (Table 2), of which 119 reported hearing WASH messaging 
during the monsoon season for a coverage rate of 30.2%. When asked which messaging 
was heard, survey respondents were most likely to report hearing about the importance of 




of the knowledge assessment can be seen in Table 4. While most respondents had heard 
of cholera and the importance of safe water, less than half thought that hand washing was 
important in prevention of disease. Univariate logistic analysis showed that those who 
had received WASH messaging were 2.5 times as likely to have heard of cholera (95% 
CI: 1.21, 5.08). Adjusting for age, sex, and education attenuated this association and the 
adjusted odds ratio was 2.33 (95% CI: 1.01, 5.37).  
 
2.5 Discussion 
The initial pilot of the CTI program in Kathmandu Valley suggests that this type of 
cholera control approach is feasible in an urban, developing country setting. Despite this 
being the first time such an approach has been used in the country, the program resulted 
in a heightened awareness of cholera and AWD in the Kathmandu Valley among 
government officials, hospital staff, and local NGOs. This increased awareness played a 
large role in the ability of the RRTs to mount a comprehensive response, rather than 
compartmentalized responses at each level of the health system.  Historically, divides 
between clinicians, laboratory staff, and the government responders have existed in 
Nepal. Clinicians treat patients based on clinical symptoms and they are often discharged 
before laboratory results are available. Combined with the very little information 
collected on these cases at admission, this scenario has made it very difficult to follow up 
on cases in the past. This implementation of the CTI approach shows the potential to 
alleviate these issues, as participants at every level were required to communicate results 




evident from hospital admission, and was successfully translated into household-level 
and in some areas community-level responses. 
 
In addition to ensuring communication between historically disparate stakeholders, the 
evaluation of the CTI approach enables us to establish a baseline for time-to-response. 
Diagnostic capacity is lacking at the hospital level, and while some hospitals do have the 
capacity to perform culture confirmation of cholera, the time required to receive culture 
results diminishes the effectiveness of a response. RRTs were able to respond to cases 
within an average of 4 days, but three of those days were typically spent waiting for a 
culture result. This highlights the need for an expansion of rapid diagnostic testing at the 
hospital level for surveillance and response purposes. The use of point-of-care RDTs 
would simplify all levels of the cholera surveillance and response system by allowing the 
laboratory staff to provide clinicians with a rapid diagnosis, and the medical recorder 
with a final diagnosis that warrants immediate report to the EDCD response team. An 
intervention could be implemented in the affected area within hours, as opposed to days, 
potentially preventing additional cases. 
 
The surveillance capacity was enhanced during this season and the hospitals benefitted 
greatly from the increased resources. In many cases, daily reports came in from the large 
government hospitals, but for others timely reporting was still a major issue. Staff 
reported being over-burdened on both sides of the system, both at the ministry of health 
and in the health facilities, making it difficult to encourage hospital reporting and 




18.5 million people, one potential solution could be to increase or re-route manpower to 
specifically work on AWD and cholera surveillance at the district level during the 
monsoon season to ensure all cases are being identified, reported, and responded to. 
Lessons could also be taken, and trainings created for the less-responsive hospitals, based 
on those that did report daily even when no cases were seen.  
 
The bar set for a “rapid” response under the CTI approach was to respond to the home 
within 24 hours of a case presenting to the facility. RRTs were able to perform thorough 
investigations at the homes of just over half of the confirmed cholera cases, but it took 
four times as long as planned. Several issues were at play here that can ultimately be 
traced back to the hospital-based surveillance. First, the vast majority of cases that could 
not be followed up with household investigation were due to a lack of, or incorrect, 
contact information for the patient in the medical record. This is often a direct result of an 
over-burdened and understaffed hospital where the accuracy and completeness of patient 
information is not a top priority. The EDCD officials’ uncertainty around the use of 
RDTs for case confirmation was a second time-limiting factor. Their preference to wait to 
call a case confirmed (and thus initiate the household intervention) until the case had 
been confirmed by culture led to major delays in response. To alleviate this hesitancy, 
culture was performed in parallel with the RDTs, resulting in a sensitivity and specificity 
of 90% and 70%, respectively. These numbers support a system in which a response can 
be initiated by RDT result, and culture can still be used at the national level as gold 
standard confirmation. Especially in cases where an outbreak has already been detected 




many as six days to respond after culture confirmation. There were only two central-level 
RRTs devoted to cholera response during the CTI implementation and as the outbreak 
progressed and daily case count increased, it was more difficult to keep up with 
household investigations. Manpower issues are a common constraint in Nepal, and one 
that will need some serious commitment by the government to solve sustainably.  
 
There is no real mechanism for initiating rapid interventions in Nepal’s health system. 
Prior to implementing WASH interventions, planning meetings needed to be held at the 
district level, even when the same intervention had already been carried out in another 
area of the same district weeks earlier. On average it took teams nine days to agree upon 
a location to perform an intervention and obtain the necessary approval to carry it out. 
While ensuring a quality response is important, it is clear that there is a great need for 
standard interventions to be agreed upon and planning meetings and trainings to be held 
prior to the cholera season.   
 
Another major issue with the WASH response was targeting of the intervention. While 
the program was designed to target those households immediately surrounding a case, 
interventions were planned and implemented more broadly. The intention was to reach 
more people at risk, but the result was low coverage of the intervention. In addition to 
needing a more rapid response, these results seem to highlight the need to narrow the 
population target for the interventions. However, the interventions themselves did appear 
to have a positive impact on knowledge in those that received them. One key exception 




WASH alongside vaccine to maximize protection. Most survey respondents could name 
prevention methods for cholera, but very few named vaccination as one of them. This is a 
major gap in the education provided in these interventions that would need to be filled if 
the program is to be fully implemented, and succeed, in the future. 
 
A key element of the CTI response was the monitoring of water sources. Nearly all 
sources were contaminated beyond levels safe for human consumption, however only 
three water sources were found to be positive for cholera during the household 
investigations. This sheds light on the state of the water system in Nepal, and the 
incredible vulnerability of the nation’s poor. It is no surprise that improvements are 
needed in the water and sanitation infrastructure around the country, and steps are being 
taken, especially in light of this new data. This can serve as a reminder of how 
interventions such as WASH and OCV can be leveraged to prevent morbidity and 
mortality while those improvements are made.  
 
The inability to obtain OCV within the program period was a significant obstacle, but it 
led to a discussion of the need for a small national vaccine stockpile. Without adequate 
knowledge of disease burden on which to base a pre-emptive vaccination campaign, the 
proposed reactive strategy provides an efficient alternative. A small stockpile would 
allow the ministry of health to respond quickly to seasonal outbreaks, but would also 
provide a safety net in the event of a large outbreak while more resources are being 






This is an analysis of feasibility, and there was no attempt to determine the effectiveness 
of the CTI approach. Measuring effectiveness would require randomization to non-
intervention groups and careful consideration of the ethical concerns, but may be 
considered in the future. Timeliness and practicality were the main criteria used to 
determine feasibility, however, cost is also a large determinant of feasibility that was not 
considered in this analysis. 
 
Another potential limitation was the six to eight month lag between the implementation 
of the WASH interventions and conducting the household survey. Despite the 
implications for recall and therefore the reliability of the coverage estimate, the results of 
the knowledge portion of the survey are highly informative. Whether or not the family 
received or remembered the intervention itself, the results reveal the proportion of the 






The CTI shows promise as a strategy to unify effective cholera control procedures.  We 
understood that this approach would represent a major change in the current procedures 
for cholera management, since case management, laboratory assays, and public health 




case quickly and arrange for a rapid test to be carried out.  The technician carrying out the 
test would quickly notify the EDCD of the positive case, and the CTI-RRT could quickly 
(within 48 hours of the case coming for treatment) visit the neighborhood and implement 
within this neighborhood an integrated intervention package including WASH, health 
education, community mobilization and vaccination. Upon its first implementation this 
timeline has been extended, but through this evaluation we have shed light on the current 
weaknesses in the cholera surveillance system and identified concrete areas for 
improvement.  
 
The CTI was successful in raising awareness and engaging stakeholders in both 
government and private sectors. While the RRT were able to investigate cases at the 
household within 48 hours of the positive culture result, the analysis identified several 
constraints that limited a truly rapid response able to target the immediate neighborhood 
of the case.  Using the information from this first year, we identified pathways that will 
be useful for future implementation of CTI. Issues with the response were extensively 
discussed post-monsoon season and solutions were integrated into the country’s first 
national cholera control plan. Armed with this experience, increased awareness, available 
doses of vaccine, and a government and stakeholder-endorsed plan, the CTI approach has 
the potential to prevent the spread of cholera in the Kathmandu Valley, and eventually 











































Figure 2.1 CTI ring strategy. A 100m ring is approximately identified around an index 
case (shaded area). Intervention households are indicated by points, and specific 






Figure 2.2 Epidemic curve in Kathmandu Valley, Nepal 2016. Confirmed cholera 
cases shown in bars, and defined as all individuals who are positive for V. cholerae by 









Figure 2.3 Geographic distribution of cholera cases in Kathmandu Valley, 2016. 







Figure 2.4 CTI surveillance and response performance. Bars indicate the time from 
hospital admission of the index case to initiation of a WASH intervention in the 
neighborhood of that case. Data is only shown for cases in which complete date 
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3.1 Paper Two Abstract 
3.1.1 Background 
Limited data exists on the molecular characteristics of Vibrio cholerae in Nepal. 
Techniques such as PCR and MLVA can revitalize surveillance and response, not only in 
terms of time to diagnosis and response, but also for understanding the molecular 
epidemiology of the disease. We evaluated the genetic diversity of V. cholerae clinical 
samples during a 2016 outbreak of cholera in the Kathmandu Valley.   
 
3.1.2 Methods 
Hospital-based surveillance took place at 15 sites within the Kathmandu Valley between 
June 1st and December 30th 2016. A total of 180 stool samples were collected on filter 
paper from suspected cholera patients during this period and stored for molecular testing. 
These samples were tested for cholera via PCR, and the genetic relatedness of positive 
samples was determined by comparing alleles at five loci containing a variable number of 
tandem repeats. These results were compared to bacterial culture results obtained during 
the outbreak, and to previously reported MLVA genotypes from Nepal and elsewhere. 
 
3.1.3 Results 
Diagnostic testing via PCR revealed an additional 24 clinical samples positive for V. 
cholerae O1, bringing the total number of confirmed cholera cases during the 2016 
outbreak from 169 to 193. MLVA genotyping showed minimal genetic diversity, with 




previously identified in Nepal. However, some relatedness was seen between the 2016 
Nepal samples and large chromosome (three loci) genotypes seen in other countries. 
 
3.1.4 Conclusion 
The minimal diversity seen in these clinical samples combined with the shape of the 
epidemic curve seems to indicate a clonal outbreak consistent with a common source 
outbreak followed by secondary fecal-oral spread from person to person. Thus, it seems 
unlikely that there were multiple endemic environmental sources for V. cholerae in the 
Kathmandu Valley in 2016. The results also highlight how PCR can be used as a way to 
monitor for false negatives obtained via bacterial culture for cholera in the hospital labs 

















Cholera is caused by ingestion of the bacterium Vibrio cholerae and presents clinically as 
the rapid onset of acute watery diarrhea, often referred to as rice-water stool, and 
vomiting. Without treatment the disease can progress rapidly and lead to death from 
severe dehydration in as little as four hours from onset of symptoms. A total of 51 
countries are classified as endemic for cholera, with six of these countries in South East 
Asia including Nepal and its neighbors China and India.[90] Nepal’s Kathmandu Valley 
routinely experiences cholera outbreaks during the annual monsoon season from June to 
August.[91-94] 
 
Due to the increased risk for cholera transmission resulting from the 2015 earthquakes in 
Nepal, an enhanced hospital-based surveillance system was established in the Kathmandu 
Valley. From June 30th to December 30th 2017, a total of 169 cases of cholera were 
diagnosed in hospitals around the Kathmandu Valley and confirmed via bacterial culture 
by the National Public Health Laboratory (NPHL) of the Nepal Ministry of Health. 
 
As part of the enhanced surveillance system, stool samples were collected on filter paper 
for suspected cholera patients presenting to one of the surveillance sites. These samples 
can be used for molecular testing and have the potential to drastically shorten the time to 
confirmation and improve outbreak response and the understanding of cholera 
epidemiology in the area. In comparison to culture, the use of polymerase chain reaction 
(PCR) for detection of V. cholerae in the stool takes hours as opposed to days. This not 




sooner to prevent further infections. PCR also allows increased flexibility in the type of 
sample required for testing. A fresh stool sample is required for culture, which may be 
difficult to deliver to a national lab if the hospital is experiencing a high burden or is 
located in a remote area. A filter paper sample does not need to be refrigerated and is 
non-biohazardous once dry, avoiding these issues and still allowing for the confirmation 
to take place.  
 
Outbreak response can also be improved through the use of more advanced molecular 
techniques, such as multi-locus variable-number tandem-repeat analysis (MLVA) which 
can differentiate among isolates and determine whether an outbreak over a wide 
geographic area is due to a single or multiple sources. This information can also be used 
to link cases and combined with GPS data, to track the spread of the disease in an area.  
 
There has been very limited genetic characterization of cholera in Nepal. While V. 
cholerae isolates collected through routine antimicrobial resistance surveillance have 
been characterized previously, this is the first instance of longitudinal genetic analysis of 
a single cholera outbreak in Nepal.[95,96] In order to better prepare for response to 
cholera outbreaks, it is important to understand the relationships between strains. This 
work aims to determine the relatedness and potential avenues of transmission of V. 
cholerae strains circulating in the Kathmandu Valley and highlight the importance of 







3.3.1 Sample Collection 
A total of 180 stool samples were collected as part of a hospital-based surveillance 
system for cholera at 15 sites within the Kathmandu Valley between June 1st and 
December 30th 2016. A standard case definition was used to differentiate cholera: Acute 
watery diarrhea (AWD), with or without vomiting, in a patient aged one-year or more. 
Stool samples from patients meeting the clinical case definition were inoculated into 
Cary-Blair transport media and sent for culture confirmation and serotyping at the 
National Public Health Laboratory (NPHL). These stool samples were also spotted on 
Whatman 903 filter paper cards (Whatman 903 Protein Saver Card, GE Healthcare Ltd., 
Forest Farm, Cardiff, UK) for later PCR detection and molecular testing.[62] 
 
3.3.2 Bacterial Culture and Antimicrobial Resistance Testing  
Cary-Blair specimens were streaked onto thiosulfate citrate bile salt sucrose (TCBS) agar 
upon arrival at the NPHL and incubated at 37°C for 24 hours. Following incubation, the 
plates were visually screened for the yellow colonies indicative of V. cholerae. After 
subculture, single colonies were tested for agglutination in anti-O1 and anti-O139 sera to 
determine the serogroup, and in Ogawa and Inaba anti-sera to determine serotype. 
Antimicrobial resistance was determined using standard disc diffusion methods for 







3.3.3 DNA Extraction 
Filter paper samples were transported to the US in bulk, after the outbreak in Kathmandu 
had subsided. DNA was extracted from the dried stool spots similar to published 
methods.[84] Dried stool spots were cut from the filter paper cards using sterile scissors 
and then placed into a sterile, labeled tube with 1mL of sterile phosphate buffered saline 
(PBS). After a 10 minute, room temperature incubation, the sample was centrifuged at 
14K RPM for 2 minutes and the supernatant was discarded. Two hundred µL of distilled 
water was added to the tube, which was then incubated for 8 minutes at 100°C. The 
sample was then centrifuged for 1 minute at 14K RPM and the supernatant was 
transferred to a new, sterile tube for storage at -20°C. 
 
3.3.4 Polymerase Chain Reaction 
Each sample was confirmed for cholera using a series of multiplex PCR tests. The first 
identifying samples containing the cholera toxin gene (ctxA) and a gene encoding for the 
cholera outer membrane protein (ompW), and the second differentiating O1 from 
O139.[98-100] 
 
The first reaction was run in a total volume of 25 µL, containing 5 µL of DNA extracted 
from the dried stool spots, 1x Terra PCR Direct Buffer (with Mg2+, dNTP), 0.5 U Terra 
PCR Direct Polymerase Mix (Clontech Laboratories, Inc., Mountain View, California, 
USA), 0.4uM of ompW forward and reverse primers, and 0.25uM of ctxA forward and 
reverse primers. PCR conditions were optimized at initial denaturation of 2 minutes at 




64.4°C for 15 seconds, and extension at 68°C for 36 seconds, with a final extension step 
of 68°C for 7 minutes.[98] The amplified PCR product was analyzed by gel 
electrophoresis on a 2% agarose gel for 50 minutes and visualized under UV light with 
ethidium bromide.  The amplified products for ompW and ctxA are 588 and 302 base 
pairs in length, respectively. 
 
Any specimens that tested positive for V. cholerae in the first multiplex PCR reaction 
were tested to determine if they belonged to serogroup O1 or O139 with a second 
multiplex PCR reaction. The second reaction was run in a total volume of 25µL, 
containing 5 µL of DNA extracted from the dried stool spots, 1x Terra PCR Direct Buffer 
(with Mg2+, dNTP), 0.5 U Terra PCR Direct Polymerase Mix (Clontech Laboratories, 
Inc., Mountain View, California, USA), 2µM of O1-rfb and O139-rfb forward and 
reverse primers, and 0.8uM ctxA (VCT1, VCT2) forward and reverse primers. PCR 
conditions were optimized at initial denaturation of 2 minutes at 98°C, followed by 30 
cycles each with denaturation at 98°C for 15 seconds, annealing at 57°C for 15 seconds, 
and extension at 68°C for 29 seconds, with a final extension step of 68°C for 7 
minutes.[99] The amplified PCR product was analyzed by gel electrophoresis on a 2% 
agarose gel for 50 minutes and visualized under UV light with ethidium bromide. The 








3.3.5 Multi-locus Variable-Number Tandem-Repeat Analysis 
Specific primers (Table 1) and PCR conditions were used to amplify the sequences of 
five loci in the cholera genome (VC0147, VC0437, VC1650, VCA0171, and VCA0283) 
each repeated a variable number of times (between 4 and 31 repeats).[101-103] Three of 
the loci are found on cholera’s large chromosome (VC1047, VC0437, and VC1650) and 
two on the small chromosome (VCA0171 and VCA0283). The large chromosome loci 
are typically more stable than those on the small chromosome, although there is some 
recent evidence that suggests this is not always the case.[101,104,105] 
 
PCR reactions were run in a total volume of 30µL, one for VC0147 and VCA0171 and 
the second for VCA0283, VC0437 and VC1650. Each reaction contained 1 µL of DNA 
extracted from the dried stool spots, 10x Buffer (with 50mM Mg2+ and 10mM dNTPs), 
5U Taq Polymerase, and 10µM each of forward and reverse primers. PCR conditions 
were optimized for each set of primers. VC0147 and VCA0171 had an initial 
denaturation of 5 minutes at 95°C, followed by 35 cycles each with denaturation at 95°C 
for 1 minute, annealing at 58°C for 45 seconds, and extension at 72°C for 1 minute, with 
a final extension step of 72°C for 4 minutes.  VCA0283, VC0437 and VC1650 had an 
initial denaturation of 5 minutes at 95°C, followed by 35 cycles each with denaturation at 
95°C for 1 minute, annealing at 55°C for 45 seconds, and extension at 72°C for 1 minute, 
with a final extension step of 72°C for 4 minutes.  The amplified PCR products were 
analyzed by capillary electrophoresis. The number of repeats at each locus was 
determined by using a 3730xl automatic sequencer and internal lane standards (600 LIZ 




Biosystems, Foster City, CA, USA) and the formulas seen in Table 1. The five loci were 
ordered by their location on the chromosome and a five number genotype was assigned 
based on the number of repeats at each of the loci. The relatedness of each isolate was 
determined by comparing the genotypes using eBURST software (http://eburst.mlst.net) 
that predicts the founding genotype and how it branches to subsequent genotypes. Groups 
of related genotypes, derived from the same ancestor, are called clonal complexes. 
Genotypes that are genetically related possess identical alleles at four of the five loci. 
 
3.4 Results  
A total of 180 stool samples were collected on filter paper at health facilities around the 
Kathmandu Valley and transported to Baltimore for molecular testing. Of these samples, 
118 were simultaneously sent in Cary Blair for culture confirmation on TCBS at the 
NPHL. Sixty-two of the samples were collected on filter paper only, as they could not be 
transported within 48 hours of collection, and therefore not confirmed by culture. 
 
The results of the diagnostic testing by culture and PCR can be seen in Figure 1. Of the 
cases for which filter paper was available, bacterial culture confirmed 112 cases of V. 
cholerae O1 Ogawa and 2 cases of V. cholerae O1 Inaba. All 114 cases revealed an 
identical antimicrobial resistance pattern, with sensitivity to ciprofloxacin, azithromycin, 
tetracycline, and ceftriaxone, and resistance to cotrimoxazole, ampicillin, and nalidixic 
acid. PCR confirmed that 138 of the 180 total filter paper samples contained V. cholerae 




the cholera toxin gene (ctxA) as the gold standard. Culture was found to be 97.44% 
sensitive and 100% specific. 
 
When combining cases previously deemed positive by culture (N=169) with those newly 
identified by PCR (N=24), a total of 193 cholera cases reported to hospital surveillance 
sites during the surveillance period (Figure 1). The revised epidemic curve for the 2016 
outbreak can be seen in Figure 2. Note that nine of the PCR cases are not included in the 
epidemic curve, as admissions date information was unavailable for those samples. 
 
Only two of the five loci exhibited genetic variation. VC0147, VC0437, and VC1650 had 
only a single allele, while VCA0171 had six alleles, and VCA0283 had five alleles 
(Figure 3). These alleles made up a total of eight genotypes from a single clonal complex 
(Table 2). Of the two samples positive for V. cholerae O1 Inaba, one was of the founding 
genotype (9-4-6-12-23) and the other shared a single-locus variant genotype (9-4-6-13-
23) with three V. cholerae O1 Ogawa cases.  
 
3.5 Discussion 
Over the seven-month surveillance period, a total of 193 cholera cases reported to 
hospital surveillance sites throughout the Kathmandu Valley. Beginning approximately 
one month into the surveillance period, the outbreak lasted five months, well past the end 
of Nepal’s monsoon season. MLVA genotyping of 138 stool samples, which were 
positive by PCR for V. cholerae O1 revealed minimal diversity, indicating a clonal 




epidemic curve shown, leads to the assumption that this was a common source outbreak 
followed by secondary person-to-person spread. This is corroborated by the few 
deviations seen in genotype over time and only one clonal complex, despite cases being 
seen in multiple districts. Thus, it seems unlikely that there are multiple endemic 
environmental reservoirs or multiple introductions into Kathmandu Valley. In 2016, 
Nepal was still struggling with the disruption of already sub-par water and sanitation 
infrastructure triggered by the 7.8 and 7.3 magnitude earthquakes of 2015. The most 
likely scenario is one in which the overpopulation of the capital, combined with the 
favorable climate of monsoon season and less than ideal sanitation conditions, led to the 
opportunity for local transmission of V. cholerae.  
 
None of the eight genotypes reported in this study have been reported previously in 
Nepal. A 2012 analysis of V. cholerae strains from 2007 to 2010 revealed a total of 4 
clonal complexes over the time period isolated around the country as part of their 
antimicrobial resistance surveillance system.[95] The strains previously identified in 
Kathmandu differ from the 2016 strains. No reports of MLVA genotype have been 
published since 2012 and MLVA analysis is typically only useful for analysis of isolates 
collected within a short period of time and small geographic area.[104] However, some 
evidence suggests that the loci on the large chromosome (VC0147, VC0437, and 
VC1650) are the most stable and are thought to be the best set for estimating relatedness 
between strains across large distances.[101,104] When comparing MLVA genotypes of 
only the three large chromosome loci, the (9-4-6) profile seen in Nepal is related to the 




Mozambique (2003 & 2009), and Cameroon (2014).[62,101,103,104] Mozambique also 
reported minimal diversity over a much longer period of time (2002-2012). Cameroon 
and Bangladesh however, saw greater diversity.  
 
While it may be tempting to conclude that this outbreak in Kathmandu Valley was caused 
by an introduction from a recent traveller from another endemic area or nation [106], data 
on cholera in the Kathmandu Valley suggest that outbreaks are a common occurrence 
especially during the summer monsoon period. Cases began being officially reported as 
part of Ministry of Health Annual Reports in 2013, and have been documented in the 
Kathmandu Valley every year since, even prior to the major earthquakes.[81] Cholera has 
long been considered endemic in Nepal, and while these results do not corroborate an 
endemic environmental source in the Kathmandu Valley, they certainly do not exclude 
the possibility. One explanation for this type of yearly, clonal spread could be the 
presence of a reservoir outside of the Kathmandu Valley, but still within the country of 
Nepal. Travel to the capital city from distant districts is very common, especially as roads 
improve and air travel becomes more affordable. Poor surveillance infrastructure in the 
rural and/or distant districts could explain why cases are annual in the Kathmandu Valley, 
but perceived to be sporadic in other parts of the country. 
 
Bacterial culture on TCBS for V. cholerae is very sensitive and specific, but may miss 
some cases. This is especially important when dealing with outbreaks in distant or hard to 
reach areas. The filter paper specimens collected during this outbreak were stored for 




were easy to collect, store, and ship since they are not biohazardous, and easy to test in a 
laboratory that is not necessarily on site. These results demonstrate the utility of PCR to 
identify additional cases in these instances. This highlights the importance for this 




This study has contributed to the further understanding of the molecular epidemiology of 
cholera in the Kathmandu Valley, but with limitations. All 180 samples were from a 
single outbreak, and therefore tell us very little about the genetic changes in V. cholerae 
over longer periods of time. Previous studies provide some genotype information that can 
be used for comparison, but the gap in time between studies makes it difficult to connect 
them. Samples were not consistently collected from all patients meeting the case 
definition during the outbreak due to several logistical variables. High technician 
turnover in hospital labs often led to confusion in the study protocol, Many times this 
resulted in filter paper samples being collected for culture positive samples only, if at all. 
This was in addition to a high caseload during the height of the outbreak, making the 
extra collection step more difficult in an already over burdened system. As a result, 
additional culture negative but PCR positive cases may have been missed. It is important 
to note that these results pertain only to the Kathmandu Valley, as the enhanced 







This genetic characterization suggests that the most recently recorded outbreak of V. 
cholerae in the Kathmandu Valley resulted from a common ancestor strain that then 
spread throughout the area, and was most likely aided in transmission by favorable 
environmental conditions and human hygiene behaviors. This data on strain uniformity 
has furthered our understanding of the epidemiology of this outbreak, and shed light on 
the potential usefulness of investing in capacity building for molecular techniques at the 
national level. The filter paper method of collecting stool specimens for later testing at a 
laboratory equipped for molecular testing has the potential to reduce under-reporting in 
documented outbreaks and increase detection of outbreaks in remote areas. This is true 
not only in Nepal but also in any country with hard to reach areas that lack access to 
microbiology laboratories. Without a functional, comprehensive surveillance system the 
true burden of cholera in Nepal, and triggers for its emergence and transmission around 

























































Figure	3.1	Diagnostic testing for cholera by bacterial culture and PCR. A total of 
169 cholera cases were confirmed during the 2016 outbreak in Kathmandu Valley. 180 
samples were collected on filter paper and tested several months post-outbreak via PCR, 










































Figure 3.2 Cholera cases per day between June 30th and November 13th 2016. 
Each box represents a single case. Dark boxes represent cases originally identified by 
bacterial culture (n=169). White boxes represent additional cases detected via PCR of 
stool samples collected on filter paper (n=15). Note: Nine samples did not have 























































Figure 3.3 MLVA genotypes. A single MLVA 
clonal complex responsible for a 2016 outbreak of 
cholera in the Kathmandu Valley. Boxes represent 
single genotypes (n=8) and lines represent a single 
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4.1 Paper Three Abstract 
4.1.1 Background 
Despite the availability of effective tools for controlling cholera, it has remained a 
challenging task; millions are still being affected each year with thousands of deaths. In 
some cases, a cholera vaccine is being used to control the outbreaks targeting high-risk 
populations without complete knowledge of their risk status, requiring millions of doses. 
A ring vaccination strategy targeting the population living around the case was found to 
be useful in eradicating smallpox and lately in controlling the Ebola outbreak in Guinea. 
However, such a vaccination strategy has not been evaluated for its ability to stop the 
transmission of cholera. In mid-2016, a cholera outbreak occurred in Kathmandu Valley, 
Nepal. This study aims to determine if a reactive, ring vaccination strategy would have 
been useful in preventing cholera transmission during that outbreak. 
 
4.1.2 Methods 
Data on cholera cases were collected as part of hospital-based surveillance for cholera in 
the Kathmandu Valley from June 30th to November 30th 2016. Cases were confirmed by 
bacterial culture and/or polymerase chain reaction testing. Subsequent household visits 
were made to obtain GPS coordinates of the case households. Geographic clusters of 
cases were visually determined based on potential transmission patterns in space and 
time, and tested for clustering using Ripley’s K and L functions. The cluster size was 
determined based on the distribution of cases around the index case and reasoning that 




index case had been vaccinated. The underlying population within each ring was 
estimated based on 2011 census data. 
 
4.1.3 Results 
A total of 193 cholera cases were reported during the surveillance period, of which GPS 
coordinates of 69 cases were captured. The peak of the outbreak occurred 7 to 10 weeks 
after the onset. Six geographic clusters were determined, all of which showed significant 
clustering of cases. Approximately 85% (52/61) of the cases within a cluster occurred 
more than seven days after the index case. Median ring size was 1km with a population 
of 14,000 people. 
 
4.1.4 Conclusions 
Cholera cases during the outbreak were clustered in space, and the majority of cases 
occurred over a week after the initial cases in the cluster, allowing for an opportunity to 
prevent transmission of the disease through use of the vaccine soon after the initial case 
was identified. This would require only 14,000 doses per cluster when using a single dose 
strategy. A ring vaccination strategy may be especially useful for large urban areas with 












Cholera remains a significant public health problem in several countries around South 
East Asia.[90] Six countries in the region are considered endemic for cholera, including 
Nepal, with an estimated 485 million people at risk. Out of the 818,514 cases and 24,509 
deaths estimated to occur annually due to cholera in the region, Nepal accounts for an 
estimated 30,379 and 911 respectively. These estimates are primarily based on the 
proportion of people in Nepal without access to improved water (11%) and sanitation 
(69%) facilities.[90] Cases have been reported sporadically in multiple districts around 
the country and annually in the Kathmandu Valley over the last 5 years.[81] 
 
Environmentally driven by contaminated waterbodies and seasonal monsoon rains, the 
disease is subject to secondary spread through fecal-oral transmission.[107] While the 
primary transmission is responsible for endemicity, it is this person-to-person spread that 
determines the magnitude of the outbreak.[108] Plentiful data exist in support of 
cholera’s spatial and temporal associations.[77,78,109-112] The closer a person lives to a 
cholera case, the higher the risk of contracting the disease by that person. Thus, cholera 
cases tend to be spatially clustered. This observation has led to recent research into the 
potential for controlling outbreaks via a ring vaccination strategy with a single dose of 
oral cholera vaccine (OCV). OCV has been shown to be effective in the prevention and 
control of cholera outbreaks as well as endemic settings.[70] Two-doses of OCV 
provides over 80% protection during the first 6 months after vaccination. While a single-
dose strategy lowers the effectiveness, it has still been shown to provide significant short-




supply is limited.[71] The evidence suggests that vaccinating a buffer of individuals 
around an index case, when implemented immediately upon case confirmation, could 
ultimately halt secondary transmission and prevent the disease from spreading to new 
areas.[71,77]   
 
Nepal is known to be endemic for cholera, but poor surveillance makes narrowing the 
target population through hotspot identification problematic. Despite these limitations, 
the endemic nature within Nepal and the explosive, epidemic potential of the disease 
given the plethora of risk factors existent in the Kathmandu Valley makes cholera a 
public health priority. 
 
An outbreak of cholera occurred in the Kathmandu Valley during the summer monsoon 
months of 2016. This study aims to determine if a reactive, ring vaccination strategy 
could have been successful in preventing cases once the outbreak began. This 
determination begins by exploring the transmission patterns of cholera in space and time 
during the outbreak, with a particular focus on the spatial clustering of the cases.  
 
4.3 Methods 
4.3.1 The Study Area and Population 
The study was conducted in Nepal’s Kathmandu Valley comprising three districts: 
Kathmandu, Lalitpur, and Bhaktapur. It is the most developed area of Nepal, and is 
surrounded by four mountain ranges (Figure 1).  Outbreaks of cholera in Kathmandu 




August.[91-94,113] As per the 2011 census, there were 119 wards in these three districts 
with a population of about 2.8 million.[114] 
 
4.3.2 The Cholera Data 
Data on cholera cases were collected as part of hospital-based surveillance for cholera in 
the Kathmandu Valley from June 30th to November 30th 2016. A line listing including 
hospital admission date was maintained for all suspected cholera cases from the 14 
chosen hospitals. Fecal specimens from the suspected cases were sent from the hospitals 
to the National Public Health Laboratory of the Ministry of Health Nepal, who then 
notified the Ministry’s Epidemiology and Disease Control division (EDCD) of any 
culture confirmed cases. A rapid response team then attempted to obtain permission for a 
visit to the home of the index case to collect additional information on the case.  
 
4.3.3 The Geographic Data 
The geographic data of administrative units (district and ward boundaries) and rivers 
were obtained from the Ministry of Health, Nepal. As the part of the household 
investigation, GPS locations of the case households were obtained using a mobile 
application (KoBo Toolbox, Cambridge, MA, USA) setting World Geodetic System 
(WGS) 1984. The GPS surveyor was trained to utilize a standard length of time (~10 
minutes) to take the GPS readings. The time frame was chosen to assure sufficient time 
for the GPS receiver to obtain required satellite signals to increase positional accuracy of 
each reading. Receivers were held static and barrier-free while getting the readings. The 




accuracy of the data. In addition to case household locations, the locations of the health 
centers performing surveillance in the study area were collected using a similar 
technique.    
 
To view and display the landscape of the study area, satellite imagery data of the study 
area was extracted from Google Earth Pro, which was then georeferenced in the same 
WGS-1984 projection so that the imagery could be superimposed on to the digital map of 
the study area.  
 
4.3.4 Spatial Analysis 
The geographic clusters of the cholera outbreak were defined within the study area using 
visual analysis. The outbreak’s index case (the 1st case inside the study area) along with 
the index case in each cluster (1st case within the cluster) were identified by hospital 
admission date. Linear distances (meters) and times (days) of the secondary cases were 
calculated in relation to the location and date of presentation of the index case in a 
cluster.  Before calculating linear distance, the geographic data was transformed from 
WGS-1984 projection to Universal Transverse Mercator Zone-45 North projection. The 
distance and time of the index case of each cluster from that of the outbreak index case 
was also calculated. Cases were plotted based on distance and time in order to postulate 
transmission dynamics within a cluster.  
 
Spatial clustering of the cases was assessed using Ripley’s K-function for the cholera 




cases within a range of distances of other cases. To account for the effects of complete 
spatial randomness, the L-function, which is a variance stabilized transformation of the 
K-function, was also plotted. The estimates were plotted as a function of distance along 
with a Monte Carlo assessment of complete spatial randomness to account for 
uncertainty. Both K and L function analyses were performed using “spatstat” 
implemented in the R Statistical software, and mapping was done using ArcGIS 10.5.1 
(Esri Inc). 
  
The maximum distance from the index case to a subsequent case was recorded for each 
cluster. This was done for cases occurring within 14 days of the index, reasoning that 
further spread of transmission would have been stopped covering the cases occurring 
within 14 days of the index case. Circular rings around each cholera index case were 
drawn using the median distance of the clusters. The underlying population within each 
ring was estimated based on the area of the ring overlapped with the area of the ward. 
Note that the ward is the lowest administrative unit of the Ministry of Federal Affairs and 
Local Development in Nepal. The ward population was based on the Nepal’s 2011 







pj is the population in ring j, wi is the population in ward i, rj is the ring j area overlapped 







During the outbreak a total of 193 cases of Vibrio cholerae O1 were reported to the 
Ministry of Health in the Kathmandu Valley through the hospital-based surveillance 
system. The epidemic curve shows the peak period of the outbreak was 7 to 10 weeks 
from the date of the initial case of the outbreak (Figure 2). Out of 193 cases, the GPS 
coordinates of the case households were available for 78 households of which 9 locations 
were outside the study area, leaving 69 cases for the spatial analysis (Figure 3).  
 
The spatial distribution of those 69 cases was plotted on a map that clearly shows spatial 
patterning of the cases (Figure 4). Using visual analysis of the spatial distribution of the 
cases and transmission patterns in space and time (Figure 5), six geographic clusters 
were defined. Global and local (within each of the clusters) clustering of the cases was 
supported by both the Ripley’s K and L functions (Figures 6A – B for global clustering 
and Figure S1A – B for local clustering of the cases). In the local cluster analysis, two 
cases were excluded for which the locations were deemed outliers, as they did not fall 
within any of the six clusters.   
 
An average of 11 cases were observed in a cluster, with a median cluster duration of 38 
days (Table 1). Median of the average distance of the subsequent cases in each cluster 
from the initial case was 0.79 km (Table 1).  85% (52/61) of cases within a cluster 
occurred more than seven days after an index case reported to the hospital (Figure 7), 
and 44% (27/61) were within 14 days of the presentation. The median of the maximum 




(Table 2). Population sizes ranged from 9,917 people in cluster 2 to over 65,000 in 




The results of our study suggest that although the outbreak continued for approximately 4 
months, the peak was of short duration (4 weeks) as is found in many other situations in 
Nepal.[115-117] It is noticeable that although the second case occurred in the same place 
within a weeks time and was likely due to person-to-person transmission, the following 
three cases occurred two weeks after the initial case presentation. Those cases were far (5 
km or more) from the initial case, thus, they were considered to have been infected from 
the local environment and subsequently transmitted the disease to others nearby over 
time. When looking at the time distribution of the cases, the majority (85%) of the 
subsequent cases were infected one week after the initial case in a cluster. This suggests 
that subsequent cases could have been prevented in each of these clusters had a 
vaccination program been initiated soon after the initial case in that area was identified.   
 
Subsequent cases within 14 days from the initial case in a cluster occurred within 1 km of 
the cluster index case. This suggests that a ring vaccination considering 1 kilometer 
around the index case would be an effective strategy in stopping transmission of the 
disease, assuming immediate action is taken by the Ministry of Health and that OCV is 
likely to provide immunity within seven days after immunization.[118,119] Such a 




the densely populated urban areas by reducing the number of doses usually used to 
combat an outbreak.[77] The Kathmandu Valley has a population of over 2.5 million and 
while the amount of available vaccine has increased dramatically over the last few years, 
demand continues to far exceed supply. Even in the event that the vaccine supply was 
limitless, vaccinating the entire population would remain logistically and financially 
infeasible. 
 
The rings with the highest populations in this study overlapped with wards of the 
Kathmandu and Lalitpur Metropolitan Cities, which have a combined population of 1.2 
million. Based on the estimated underlying population in the ring, strategies may need to 
be designed differently for the metropolitan areas where a high population density may 
lead to high risk and would require a large amount of vaccine to be available. The 
average household size for urban areas in the central development region, of which 
Kathmandu Valley is a part, is approximately 4.24.[114] Thus, the Ministry of Health 
could anticipate visiting approximately 3,300 households (14,000 persons) per ring in 
clusters to administer approximately 14,000 doses of vaccine with a single dose strategy. 
 
The cholera cases during this outbreak in the Kathmandu Valley exhibited significant 
spatial clustering, with an average size of 11 cases per cluster. This pattern indicates the 
outbreak followed the typical pattern of primary infections from a contaminated water 
source, occurring almost simultaneously in different areas of the Valley and leading to 
secondary person-to-person propagation in distinct clusters via fecal-oral 




deemed responsible for the cluster index cases, the bulk of the outbreak is likely 
determined by poor hygiene and sanitation conditions.[107,120] These results have 
practical importance in terms of the types of interventions that should be used to control 
cholera in Nepal, as well as how they should be targeted.  
 
The risk for hospitalization due to cholera was highest during weeks 7 to 10 after the 
onset of the outbreak. Atypical seasonality can also be seen, as cases continue well after 
the conclusion of the monsoon season. These observations should inform preparation 
activities and resource allocation over the course of future outbreaks, such as ensuring 
additional personnel are available for investigations and interventions in the community 
during the peak period, or that stockpiles of essential supplies are large enough to see 
response teams through an entire season.  
 
These results indicate that, within a cluster, the majority of cases occurred more than 
seven days after the cluster index case. However, previous evidence suggests that the first 
week after any cholera case, prior to when the vaccine is considered to be effective at 
preventing illness, is a high-risk period for neighbors of that case.[78] This highlights the 
importance of delivering additional interventions within this vulnerable period. There are 
strong calls for the use of water, sanitation, and hygiene (WASH) interventions to be 
coupled with OCV in these settings. As of now, there is little evidence on effective 
WASH solutions and sustainability of those solutions. A recent study in Dhaka, 
Bangladesh found that the WASH program did not reduce the number of diarrhea-related 




experts.[121] A recent meta-analysis demonstrated the protective effect of prophylactic 
antibiotics for preventing cholera among exposed household contacts, while other 
research warns of the risks of resistance over the course of an outbreak.[122-124] More 
robust research needs to be done to design impactful interventions for this high-risk 
period. Given that in this study the majority of the cases occurred one week after the 
initial case, vaccinating people surrounding the case could effectively reduce the spread 
of cholera in this instance.   
 
4.5.1 Limitations 
While this analysis was performed on a detailed dataset, the data are short term and 
limited to a single epidemic making it difficult to generalize these results to what can be 
expected in the coming years. It will be important to continue to monitor the transmission 
dynamics during future outbreaks to better refine control strategies. The analysis is also 
limited by the nature of the surveillance data being hospital-based, as it is likely that 
cases were missed within the community. Kathmandu Valley has many health facilities, 
but few with the capability for bacterial culture which was a criteria for case 
confirmation. While sentinel site hospitals were chosen in an attempt to cover the entire 
Kathmandu Valley population, travel to these hospitals would be an impractical distance 
for many households on the outskirts of the valley. Even for those making it to the 
hospital sites, not all cases consented to household follow-up. This limited the number of 
cases with complete spatial data and therefore does not show the full extent of the 




for the underlying population. It is therefore possible that the spatial pattern seen here 
might not indicate clustering of cases, but clustering of people.  
 
4.6 Conclusion 
In this study, the spatiotemporal dynamics of a single cholera outbreak in the Kathmandu 
Valley were investigated. Cholera cases during the outbreak clustered in time and space, 
a pattern that presents an opportunity to prevent further spread via ring vaccination. This 
analysis is a valuable contribution to the evidence in support of the design of a cholera 
control strategy; however, the success of such an approach requires vaccine to be readily 
available and immediately deployed upon case confirmation. The effort required for 
advanced preparation would be repaid by the prevention of both immediate infections and 
subsequent transmission of cholera to neighboring individuals and areas. It is likely that 
this strategy would require even fewer doses in a rural area outside the densely populated 
Kathmandu Valley, though further research is needed to support this hypothesis.  
Understanding that the spread of cholera in the Kathmandu Valley is predominately 
driven by secondary transmission highlights the potential for substantial spread of the 
disease in a disaster situation and the importance of improving water and sanitation 
conditions throughout the country. As annual surveillance data continues to be collected 
on cholera in the Kathmandu Valley it will not only allow for validation of these findings, 
but more in depth analysis can be performed to better understand the “typical” outbreak 
in terms of size, household risk-factors, seasonality, and identification of hotspots. This 







































































Figure 4.1 Geographic characteristics of the study area and sentinel site hospitals 






Figure 4.2 Epidemic curve of the cholera outbreak in Kathmandu valley, 2016. This 
























Figure 4.4 Spatial distribution of cholera cases by cluster.  The lines indicate 
connectivity of the cases with respect to time from the initial cases in the cluster. Circles 










Figure 4.5 Diffusion of cholera in space and time in the different geographic clusters 
in Kathmandu Valley, 2016. Triangles indicate a cluster index, along with the cluster 


















Figure 4.6 K and L functions for global spatial clustering (based on 69 cases). Black 
lines indicate the degree of clustering that was observed in the data. Red lines indicate 
what would be expected if cases were completely spatially random. The grey envelope 






Figure 4.7 Spatial and temporal dynamics of cholera cases by cluster. Distance and 






















Figure	S4.1	K and L functions for local spatial clustering (based on 67 cases 
grouped into 6 clusters). Two cases were excluded that did not fall into one of the six 
clusters. Overlap with the confidence envelope can be seen with cluster 5. This is only at 
very small distances and is likely due to the small number of cases in the cluster.	
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
 
The purpose of this dissertation was to design, implement, and evaluate an integrated 
cholera control strategy in the urban, developing country setting of Nepal’s Kathmandu 
Valley while simultaneously generating data to better understand local cholera 
epidemiology. Surveillance for cholera in Nepal is inadequate. Despite being considered 
a cholera endemic nation, with an at-risk population of over 18.5 million, very few 
resources are devoted to detecting the disease.[90] This creates a two-pronged issue: poor 
surveillance means few cases are detected and even fewer are confirmed, and lack of data 
outlining the magnitude of the problem means little assistance is offered by the 
international community to strengthen surveillance and response activities. These issues 
are not limited to Nepal and in fact have historically contributed to the limited production 
of one of public health’s key prevention measures, an effective vaccine.[76]  
 
The findings presented here show how a cholera endemic nation can make use of limited 
resources to prevent the spread of outbreaks and use the associated data to tailor future 
response efforts, gain insight on the origin of the outbreaks, and better understand disease 
transmission patterns. The reactive, ring approach outlined in Chapter 2 was carried out 
in the Kathmandu Valley during the summer monsoon months of 2016. The data 
collected during that outbreak led to increased knowledge of strain diversity (Chapter 3), 
transmission dynamics (Chapter 4), and ultimately to the development of the country’s 




5.1 Chapter Two 
The World Health Organization‘s (WHO) position on oral cholera vaccine (OCV) is that 
it “complements the other prevention and control measures and should be implemented in 
relevant settings as part of comprehensive cholera control strategies or while the other 
activities are being developed.”[125] Those other strategies include water and sanitation 
improvements, health and hygiene promotion, and strengthened disease surveillance. 
With little surveillance data to guide targeted mass-vaccination and this integrated 
approach in mind, the comprehensive, targeted intervention (CTI) for cholera control was 
born. The CTI combines a strong surveillance network and rapid response teams for 
household investigations with intensive water sanitation and hygiene (WASH) 
interventions, behavioral messaging, and vaccination. Chapter 2 demonstrated the 
feasibility of the CTI approach in the urban, developing country setting of the Kathmandu 
Valley. 
 
Highlights of the successful piloting included increased awareness surrounding cholera 
and communication between stakeholders, which allowed rapid response teams to mount 
a comprehensive response rather than compartmentalized responses at each level of the 
health system. It also shed light on the barriers to deploying a rapid response, namely the 
need for an expansion of rapid diagnostic testing at the hospital level for surveillance and 
response purposes, as well as standard interventions to be agreed upon and planning 





As far as specific components of the CTI, water sanitation and hygiene interventions 
appeared to have a positive impact on knowledge in those that received them despite low 
coverage. Lack of vaccine during the surveillance period led to the determination that a 
small stockpile could allow the ministry of health to respond quickly to seasonal 
outbreaks, but would also provide a safety net in the event of a large outbreak while more 
resources are being requested and obtained. The project also identified specific unmet 
needs for effective cholera control, such as rerouting manpower to cholera surveillance at 
the district level during monsoon season, increasing hospital staff to decrease missed 
follow-ups, and that improvements are needed in the water and sanitation infrastructure 
even in the most developed area in the country. 
 
5.2 Chapter Three 
As part of the surveillance piece of the CTI approach, stool samples were collected from 
suspected cholera cases for confirmation of Vibrio cholerae by culture and polymerase 
chain reaction (PCR), and for genetic characterization through multi-locus variable-
number tandem-repeat analysis. There has been very limited molecular characterization 
of cholera in Nepal. Chapter 3 demonstrates the minimal genetic diversity seen among 
the strains isolated throughout the course of the outbreak. Multiple explanations exist for 
a clonal outbreak, but the biggest takeaway from the data is that cholera was introduced 
from a single source and most likely aided in transmission by favorable environmental 
conditions and human hygiene behaviors.[104,107] That source could be an endemic 
environmental reservoir within the Kathmandu Valley, or an introduction into the 




knowledge that cholera occurs every year in the Kathmandu Valley, it is likely that a 
reservoir exists within the country of Nepal. 
 
Chapter 3 also emphasizes that PCR is the gold standard confirmation method for 
cholera. This is especially true when attempting to confirm outbreaks in distant or hard-
to-reach areas. Bacterial culture on thiosulfate citrate bile salt sucrose is very sensitive 
and specific, but it can miss cases, and more importantly is not feasible in many areas of 
the country. Meanwhile, stool specimens can be collected on filter paper, stored for great 
lengths of time at room temperature, and be tested at a later date for confirmation. These 
results provide a strong argument for this technology being available at the national level 
for both surveillance and response purposes. 
 
5.3 Chapter Four 
At the heart of the CTI approach is ring vaccination with a single dose of OCV. Evidence 
suggests that the greatest risk of cholera is in households neighboring an index case and 
the vaccine has been shown to provide short-term protection with just a single dose.[71] 
It was designed in acknowledgement of the lack of surveillance data as well as to be 
respectful of the limited global vaccine supply. Chapter 2 reveals the circumstances 
surrounding why vaccine was not used during this outbreak, but sufficient data exists to 
predict if it would have been successful had it been implemented. Chapter 4 confirms that 
the ring-vaccination approach had the potential to reduce the number of cholera cases 





Analysis of the locations of index case homes suggests that vaccinating individuals 
within a 1-kilometer ring would prevent many of the subsequent cases. Based on number 
of cases occurring within each geographic cluster, the average underlying population in 
the outbreak areas, and availability of vaccine, it was determined that a 1 kilometer ring 
would be a logistically feasible vaccination strategy. Once inside Kathmandu and 
Lalitpur Metropolitan Cities, the population totals approximately 1.2 million.[114] In 
addition to preventing cases, this approach would also be highly cost effective in a 
densely populated are such as the Kathmandu Valley where vaccinating the entire 
population would be infeasible.  
 
Chapter 4 also reveals a great deal about the transmission dynamics of cholera in the 
Kathmandu Valley. Corroborated by the clonal outbreak determination in Chapter 3, this 
outbreak followed the typical pattern of primary infections from a contaminated water 
source occurring almost simultaneously in different areas of the Kathmandu Valley, 
leading to secondary person-to-person spread in distinct spatial clusters via fecal-oral 
transmission. The primary take-away from this result is that poor hygiene and sanitation 
conditions are the drivers of the spread of cholera in this area. The risk for cholera was 
highest 7 to 10 weeks after the outbreak onset, with the majority cases occurring during 
the first week after an initial index case. Keeping in mind that the vaccine is not 
considered to be effective until 7 days post vaccination, these findings have important 
implications for resource allocation, preparation, and the choice of interventions to 




when to expect an increase in need for personnel can mean the difference between 
effective and sub par responses. 
 
5.4 Policy Implications – Nepal’s National Cholera Control Plan 
The results of this dissertation have important implications for cholera surveillance and 
response in Nepal. Chapter 2 highlights the successes of one approach to cholera 
response but perhaps more importantly some of the key areas for improvement. 
Understanding weaknesses in the current surveillance and response system are vital to 
creating an effective control program. Chapters 3 and 4 provide needed evidence for 
more tailored interventions by revealing molecular and spatial patterns. Translating the 
evidence into action is the cornerstone of public health practice. As part of the CTI 
program evaluation a workshop was held with stakeholders from several divisions of the 
ministry of health, district public health offices, and a number of national and 
international NGOs to discuss the lessons learned from implementing the program. The 
result of that meeting was the decision to create a national control plan endorsed by the 
Ministry of Health to aid in future outbreaks and to outline the responsibilities of each 
relevant stakeholder in cholera response. The plan was drafted over several months, with 
input from each stakeholder, and was launched in April 2017. The plan can be seen in 
Appendix 1. The hope is that this plan will evolve as the understanding of cholera 






The findings also have implications for policy in other cholera endemic nations, 
particularly in other countries where poor surveillance leaves the true disease burden 
unknown. Densely populated urban areas with inadequate water and sanitation facilities 
exist throughout Asia and Africa and are similarly at high risk for the spread of cholera 
once introduced. The proposed CTI strategy could be a useful approach for such 
situations.  
 
5.5 Recommendations for future research 
The enhanced surveillance performed during this dissertation work was concentrated in 
only three of Nepal’s 75 districts. Practically no longitudinal cholera incidence data is 
available outside of the Kathmandu Valley. More work needs to be done to understand 
how best to expand this surveillance to less developed areas of the country. It is likely 
that the risk factors differ greatly between districts. While understanding the burden of 
disease and transmission dynamics in the urban areas is important, it is only a small part 
of the full picture.  
 
Very little molecular data is available regarding the strains of V. cholerae circulating in 
Nepal year to year. Continued monitoring and MLVA analysis will allow for an 
understanding of multi-annual patterns of cholera in the country. Is the disease imported, 
or is there a reservoir, or reservoirs, that exist within the country? These types of data will 
assist in piecing the strains of V. cholerae in Nepal into the overall puzzle of cholera 





While the members of the community that received a WASH intervention during the CTI 
program appear to have more knowledge of cholera as a result, more research needs to be 
done on the effectiveness of these interventions. The findings of Chapter 4 demonstrate 
that a significant portion of the population cannot be protected by vaccination alone, even 
when rapidly delivered. This seven-day vulnerability window invites additional research 
into effective WASH and other innovative solutions. 
 
Finally, with the encouraging findings of Chapters 2 and 4, piloting the full CTI ring 
vaccination strategy in the Kathmandu Valley is the most important next step in 
evaluating the strategy. A similar ring vaccination approach was attempted in South 
Sudan, providing more supporting evidence for the approach in general, but in vastly 
different country contexts.[126] 
 
5.6 Conclusions 
In 2017, the WHO’s global task force for cholera control outlined a global strategy for 
reducing cholera deaths by 90% titled, “Ending Cholera: A Global Roadmap to 2030.” 
The document focuses on 47 cholera-affected countries, including Nepal. This 
dissertation directly addresses two of the strategy’s main mechanisms for action: early 
detection and quick response to contain outbreaks, and targeted multi-sectoral responses 
to prevent cholera recurrence.[127] The CTI approach is designed to strengthen the 
ministry of health’s ability to detect and confirm cases by utilizing new tools such as 
rapid diagnostic tests and polymerase chain reaction testing as well as increasing 




response. It is also an attempt to design a country-specific strategy for integrated cholera 
control, including WASH interventions, reactive use of OCV, and widespread health 
behavior messaging coordinated directly with enhanced surveillance. The national 
cholera control plan produced as part of this work further addresses these mechanisms by 
focusing on preparedness, stockpiling, and stakeholder coordination. The ultimate goal of 
the roadmap is to reduce cholera deaths and eventually eliminate cholera, and this will 
continue to require country-specific research to achieve. 
 
Response to an outbreak is only as good as the surveillance system used to detect it. It is 
clear that Nepal faces cholera outbreaks on a yearly basis, but the magnitude and 
geographic extent of the burden is not well quantified. More advocacy at the government 
level for investment in surveillance training and infrastructure is needed. Interventions 
such as the CTI have the potential to become even more effective with the right data and 
resources supporting them. The data generated from these interventions can then be fed 
back into the design, creating a positive feedback loop where response leads to control 
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NATIONAL PREPAREDNESS AND RESPONSE 
PLAN FOR ACUTE GASTROENTERITIS/ 
CHOLERA OUTBREAKS IN NEPAL
July 2017 to July 2022 AD
GOVERNMENT OF NEPAL
MINISTRY OF HEALTH
DEPARTMENT OF HEALTH SERVICES
EPIDEMIOLOGY AND DISEASE CONTROL DIVISION
 TEKU, KATHMANDU
MESSAGE FROM THE DIRECTOR GENERAL
Cholera is an acute intestinal infection caused by ingesting contaminated food or water with 
the bacterium Vibrio cholera. It quickly leads to severe dehydration and death if untreated. 
This plan helps the health workers at all levels to clearly understand the case definitions of 
cholera and manage the outbreaks in a standardized manner with comprehensive approach. 
The purpose of this National Preparedness and Response for Acute Gastroenteritis / Cholera 
in Nepal is, therefore, to enable all the health professionals and partners involved in health 
and WASH to manage cholera outbreaks in standardized way. The Epidemiology and Disease 
Control Division initiated to prepare the plan with support from partners in coordination with 
Task Force for Cholera Control and Steering Committee for Enteric Diseases Control, that 
would be a step ahead to prevent and control cholera. 
Department of Health Services (DoHS) hopes that this plan meets the needs of health workers 




















The development of this National Preparedness and Preparedness Plan for Acute Gastroenteritis/
Cholera Outbreaks in Nepal 2017-2022 has been a long process of consultation and engagement. 
Governmental and non-governmental stakeholders and partners have dedicated time and 
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DEFINITIONS
Acute Watery Diarrhea (AWD): The passage of three or more three loose stools per day or more 
frequent passage than in normal for the individual. 
Suspected Cholera: any person aged 3 years or more with moderate or severe dehydration from 
3 or more episodes of acute watery diarrhea per day (24 hours), with or without vomiting. 
Probable Cholera: any suspected cholera case with a positive RDT or any death in a person 14 
years or older resulting from AGE.
Confirmed Cholera: Any suspected or probable cholera case that has Vibio cholerae isolated 
from their stool by bacterial culture or PCR.
Cholera Outbreak (seasonal): A situation where cases of cholera occur in numbers similar to 
what has been seen in previous years among a specific population
Cholera Outbreak (emergency): A situation where more cases of cholera occur than are expected 
in a given area, or among specific group of people, over a particular time period (WHO EWARN).
In case of Nepal, ‘more than expected’ refers to 
i) a 50% increase in the number of cases seen in a district as compared to the average over 
the last 5 years where hospital facilities are available or 
ii) a 10% increase in the number of cases seen in a district as compared to the average over 
the last 5 years where hospital facilities are not available.  
National Preparedness and Response Plan for Acute Gastroenteritis/ Cholera Outbreaks in Nepal 1
Executive Summary
In order to guide the planning and response 
process for cholera preparedness and control 
in Nepal, the following strategy has been 
developed. This document outlines the 
current cholera situation in Nepal (as of 
January 2017) and knowledge surrounding 
interventions that are relevant in the Nepali 
context. An in-depth SWOT analysis has 
been included to shed light on the current 
strengths and weaknesses of the health 
and donor systems in Nepal, as well as 
opportunities for program improvement and 
threats to its success.
The main objective of this plan is to improve 
the overall health status of Nepal by reducing 
the incidence of cholera throughout the 
country. The plan is based on a series of 
specific objectives: to prevent the spread of 
cholera, to reduce mortality from cholera, 
to ensure a coordinated and collaborative 
response to cholera outbreaks, and to ensure 
that a rapid response mechanism is in place 
in order to successfully stop the spread of 
disease. Each objective is discussed in detail, 
with several action items included along with 
when the activities should be performed and 
who is responsible for their completion. This 
is intended to serve as both a guide and a 
source of accountability for the responsible 
parties. 
It is essential to any successful response 
program to perform routine, annual monitoring 
and evaluation. The concluding section 
of this document outlines performance 
indicators to be used to measure success 
and areas for improvement. It also details 
how this evaluation should be conducted and 
who is responsible for ensuring it is carried 
out. The results of this evaluation will be a 
valuable resource for the Steering Committee 
for Enteric Diseases and the Task Force for 
Cholera Control in their annual review of this 
plan, and coordination for the upcoming 
cholera season.
Annexes are included at the end of the 
document to assist in systematic reporting, 
ensuring proper methods, and to provide 
standardized health education materials for 
the cholera response and outbreak analysis. 
It is assumed that all humanitarian 
organizations involved in cholera response 
in Nepal will contribute to the outlined 
emergency stockpiles and follow this detailed 
plan. Moreover, It is hoped that this document 
will serve as more than just a government 
action plan, but also as a resource at all levels 
of the cholera response and for all relevant 
stakeholders.
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1. Background
Cholera: The Disease
Cholera is an acute intestinal infection caused 
by ingestion of food or water contaminated 
with the bacteria Vibrio cholerae.(1) Globally, 
it is estimated that there are 1.4 to 4.3 
million cases, and 28,000 to 142,000 deaths 
due to cholera every year.(2) Cholera has a 
direct negative impact on public health and 
economic productivity, as well as significant 
indirect costs affecting the health system, 
social welfare, tourism, trade, investments, 
etc. The threat of a cholera outbreak is a major 
public health concern for governments and 
the international health community, and a key 
indicator of lack of social development.(3)
Cholera Epidemiology in Nepal
Nepal is endemic for cholera with the potential 
for large outbreaks. While 93 percent of 
households in Nepal use an improved source 
of drinking water and 72 percent of Nepali’s 
live in households with improved sanitation 
facilities, open defecation is still practiced 
in many areas.(4) The country is also at high-
risk for outbreaks due to a steady increase 
in urban population density accompanied 
by an inadequate supply of safe drinking 
water and improved sanitation. Perhaps 
most importantly, Nepal faces flooding and 
landslides during the rainy season every 
year which often lead to the breakdown of 
the already fragile water and sanitation 
infrastructure. All of these complex factors 
raise the possibility of cholera outbreaks, 
which may be challenging to prevent and 
control. 
Outbreaks of cholera are reported in different 
regions of the country every year, causing 
the location of outbreaks difficult to predict. 
However, cases are reliably reported within 
the Kathmandu Valley every year, making it 
a priority area for cholera control in Nepal. 
While many of these cases are only clinically 
diagnosed (Table 1), several outbreaks have 
been laboratory confirmed. 
Table 1: Regional Suspected Cholera Data as Reported in the Annual Report of the Department 
of Health Services









n % n % n % n %
1 Eastern Region 2101 45.9 488 28.0 939 18.6 824 19.8
2 Central Region 825 18.0 431 24.7 2428 48.2 2616 62.7
3 Western Region 443 9.7 302 17.3 447 8.9 205 4.9
4 Mid – Western 
Region
863 18.9 115 6.6 525 10.4 54 1.3
5 Far – Western 
Region 
345 7.5 408 23.4 703 13.9 471 11.3
National 4577 100.0 1744 100.0 5042 100.0 4170 100.0
Source: HMIS, DoHS(5)
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Recent laboratory confirmed outbreaks are 
listed below:
l 2009 – Mid/Far Western Region – 1400 
clinical and 109 laboratory 
confirmed cholera cases (NPHL)
l 2010 – Mid /Western Region – 61 
laboratory confirmed cases 
(NPHL)
l 2011 – Kavre District – 1 laboratory 
confirmed multi-drug resistant 
case (NPHL) 
l 2012 – Western Region and Kathmandu 
Valley – 35 laboratory confirmed 
cases (NPHL)
l 2012 – Eastern Region – 4 laboratory 
confirmed cases (BPKIHS)
l 2012 – Doti and Dailekh Districts – 24 
laboratory confirmed cases 
(NPHL)
l 2013 – Kathmandu Valley – 4 laboratory 
confirmed cases (1 from NPHL, 2 
from Nepal Medical College and 1 
from KIST Medical College) 
l 2015 – Kathmandu Valley – 80 laboratory 
confirmed cases (NPHL)
l 2016 – Kathmandu Valley – 169 
laboratory confirmed cases 
(NPHL)
Early Warning and Reporting System (EWARS)
The EWARS was established by the 
Epidemiology and Disease Control Division of 
the Department of Health Services in 1997 
in order to strengthen the flow of information 
on vector-borne and other outbreak prone 
infectious diseases from the district to the 
national health departments. This surveillance 
system is hospital-based and is currently 
operational in 61 out of 82 sentinel sites 
throughout Nepal. So far, the EWARS mainly 
focuses on the daily and weekly reporting of 
number of cases and deaths (including “zero” 
reports) of six priority diseases, including 
acute gastroenteritis (AGE) and Cholera. It 
equally focuses on immediate reporting (to 
be reported within 24 hours of diagnosis) 
of even a single suspected case of cholera, 
as well as five or more cases of AGE from 
the same geographic location in a one-week 
period.
EWARS employs two forms of surveillance: 
indicator-based and event-based. Indicator-
based surveillance is the routine reporting 
of cases of disease, including notifiable 
disease surveillance, sentinel surveillance 
and laboratory-based surveillance systems. 
This routine reporting is commonly health-
care facility-based, with reporting on a 
weekly basis. Event-based surveillance is the 
organized and rapid capture of information 
about events that are a potential risk to public 
health. This information could be rumors or 
other ad-hoc reports transmitted through 
both formal (i.e. established routine reporting 
systems) and informal (i.e. media, health 
workers and nongovernmental organizations 
reports) channels as per need.
EWARS offers a complementary system for 
the detection of a cluster of conditions or 
unusual events, with a reduction in workload. 
In the experience of WHO’s Surveillance 
Medical Officers and their counterparts at 
the District Health Offices, the system has 
in the past been effective in tracing rumors 
or investigating potential outbreaks.  Rapid 
Response Teams (RRTs) can be mobilized 
on short notice to facilitate prompt outbreak 
response at the Central, Regional and District 
level, and can also support the local levels for 
investigation and outbreak control activities.
National Preparedness and Response Plan for Acute Gastroenteritis/ Cholera Outbreaks in Nepal4
Scientific Foundations for the Control of 
Cholera in Nepal
Antibiotic Resistance
Several studies of V. cholerae have shown 
drug resistance to a number of antibiotics. A 
brief report in 1996 was the first to discuss 
antimicrobial resistance and noted reduced 
sensitivity to nalidixic acid, co-trimoxazole, 
ampicillin, and cephalexin.(6) Almost 12 
years later in 2004, cholera isolated during 
an outbreak in Kavre district was found to be 
completely resistant to co-trimoxazole, but 
sensitive to all other antibiotics tested.(7) Another 
study conducted that year found resistance to 
nalidixic acid as well.(8) By 2008, an outbreak in 
Kathmandu (and later in Saptari and Jajarkot) 
produced isolates that were 100% resistant 
to furazolidone in addition to co-trimoxazole 
and nalidixic acid. (9-13) A later study identified 
this resistance pattern as early as 2005.(14)
Resistance to trimethoprim, sulfamethoxazole, 
and decreased susceptibility to ciprofloxacin 
was reported in 2010 and to streptomycin in 
2012.(15-16) Multi-drug resistant V. cholerae
has also been identified in Kathmandu’s sewer 
system.(17) The variation in resistance profile 
results in the need for continuous monitoring 
to ensure effective drugs are being used when 
necessary.(16)
Rapid Diagnostic Testing
Effective surveillance is needed to detect 
cholera cases during the early phases of an 
outbreak in order to mount the most effective 
response. High-quality surveillance depends 
not only on the ability to detect suspected cases 
of cholera at the health facility level, but also to 
confirm that those cases are indeed cholera in 
the laboratory (stopcholera.org). Establishing a 
high-quality disease surveillance system is not 
simple and can be both expensive and difficult, 
especially in the field with limited laboratory 
capacity, as is the case in most districts 
in Nepal. Bacterial culture confirmation of 
Vibrio cholerae has been the historical gold 
standard for cholera confirmation in Nepal, 
but it requires a well-equipped laboratory with 
trained laboratory technicians.(18)  When this is 
not available in the outbreak setting, samples 
must be transported to a reference laboratory 
which takes time, delaying the response and 
diminishing effectiveness of interventions. 
Fortunately, rapid diagnostic tests can be used 
to diagnose O1 and O139 V. cholerae at the 
point of care without a lab or technician. In 
comparison to culture, the rapid diagnostic test 
is about 90% sensitive and 60-70% specific 
in the field, but the specificity has been shown 
to increase to over 99% with the addition of 
an enrichment step.(19-24) This information 
highlights RDTs as a rapid, low-cost, simplified 
method for cholera detection in Nepal.
Oral Cholera Vaccination
Oral cholera vaccine (OCV) is an effective 
intervention for the prevention of cholera, 
especially when combined with WASH 
activities.(25) The WHO currently recommends 
three killed, whole-cell vaccines that are 
administered orally. Two of these vaccines, 
Shanchol and Euvichol, have been used in 
pre-emptive vaccination campaigns in Nepal. 
These vaccines have been proven safe, and 
are recommended for adults aged 1 year 
and over. Typically, two doses are given, two 
weeks apart which results in 85% efficacy 
after 6 months in those greater than 1 year 
of age, 45% after 5 years for those 1-5, and 
65% after 5 years for those over 5.(26-27) This 
plan recommends a two-dose strategy for 
pre-emptive campaigns. However, recent 
evidence suggests that during an outbreak 
situation, a single dose of cholera vaccine 
during a reactive vaccination campaign is 
effective at stopping transmission.(28) It has 
the added benefit of eliminating many of 
the logistical concerns that often arise from 
the delivery of a second dose to the same 
population. For these reasons, a single dose 
strategy is recommended for reactive OCV 
campaigns in Nepal.
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2. Analysis of Response Capacity (SWOT)
Strengths and Weakness
Strengths Weakness
Surveillance (( Cholera is a reportable 
disease in the Nepal 
Early Warning and 
Reporting System
(( Most cholera cases 
were tracked down 
because of early 
reporting and early 
signals
(( Daily situation 
reports and weekly 
bulletins prepared and 
disseminated to higher 
authorities (PM’s 
office, MoH, WHO, 
UNICEF)
(( Mapping of epidemics has not taken 
place systematically, making it difficult 
to create risk maps for the country
(( Surveillance reporting is incomplete 
within the EWARS system and not 
enough sentinel sites are included in the 
network (unable to detect cases from 
peripheral levels)
(( Electronic reporting system not used at 
all sites
(( Irregular zero reporting from sentinel 
hospitals 
(( Incomplete contact information recorded 
at sentinel hospitals




(( Newly developed SOPs 
were consistently used, 
resulting in adherence 
to high standard in 
culture confirmation
(( Where appropriate 
decentralize culture 
confirmation from 
national to hospital 
level
(( Samples from outside 
Kathmandu were 
transported to NPHL 
properly
(( NPHL is well equipped 
for the confirmation of 
cholera via culture
(( Long duration of incubation to conduct 
enriched RDT test (more than 6 hours) 
(( Timely availability of RDTs and supplies 
for culture confirmation 
(( Sample transport from peripheral to 
central level for laboratory confirmation 
delays response
(( SOPs do not cover how to proceed with 
testing outside normal working hours as 
samples are received 24 hours a day
(( Untrained personnel performing RDT 
and culturing
(( TCBS is not routine in outside 
Kathmandu valley
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Strengths Weakness




(( High percentage of 
cases are followed up 
at their homes and 
data collected 2016
(( RRTs are in place at 
the central, regional, 
and district levels for 
outbreak investigation 
and response
(( RRTs are not trained to conduct scientific 
outbreak investigations
(( Shortage of qualified human resources 
(e.g. field epidemiologists)No dedicated 
statisticians at any level
(( No implementation of food safety 
monitoring due to low perceived priority 
and lack of coordination with concerned 
authorities
Case Management (( Few deaths have been 
reported 
(( Antibiotics are readily 
available in hospitals
(( Many patients are discharged from 
hospital early, instead of remaining for 
fluid replacement
(( Health personnel are not trained to 
handle cases of cholera
(( Patient details are often not fully / 
properly recorded
(( Health education before discharge is not 
practiced systematically






(( Regular chlorination 
of big water supply 
systems especially 
KUKL
(( Use of field water test 
kits by response team 
– easy to use
(( Coordination with 
water tanker and 
other private service 
providers 
(( Water quality monitoring 
data as a triggering tool 
for identifying cholera 
outbreaks
(( Initiation of directives/
policy for water tankers
(( No water system mapping, which hinders 
attempts to trace sources of outbreaks 
in the system
(( Responsibilities for water chlorination 
during cholera outbreaks was unclear. 
(( Monitoring mechanism is not 
systematized to ensure regular quality – 
for microbiology
(( Lack of coordination on sharing of water 
quality testing results among WASH and 
health sector 
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Strengths Weakness
Cholera Vaccination (( Effective vaccines exist 
(( OCV has been efficiently 
deployed in the field in 
a preventative manner 
in Nepal
(( Multiple applications to the stockpile 
have been denied limiting the ability to 
deploy vaccine
(( Financial sustainability for procurement 
(( No national plan or policy on use of OCV 





for Safe WASH 
Practices
(( Optimal prioritization 
of at risk populations
(( Timely expansion of 
interventions to cover 
larger areas
(( Mass media campaigns 
reached beyond target 
areas
(( Mobilization of 
FCHVs & volunteer 
networks from affected 
communities
(( Lack of preparedness plan of BCC 
interventions 
(( Limited time for volunteer training on 
community mobilization and BCC
(( Unavailability of a dedicated team for 
monitoring
(( No funding sources of the government to 
initiate immediate response





(( Under the 
chairmanship of DoHS 
DG, technical and 
strategic direction for 
cholera control were 
provided by Steering 
Committee for Enteric 
Disease Control 
and Disaster Health 
Working Group 
(( Most outbreaks are 
small and localized 
making them easier to 
respond to and contain
(( Good coordination 
between EDCD, NPHL, 




(( Perception that overall case numbers 
are small, leading to low priority on 
government health agenda and little 
donor support
(( No monitoring and enforcement of food 
safety regulation for small restaurants 
and street food vendors 
(( Public health issues were low priority in 
municipality
(( Lack of coordination with food vendors
(( Instituting a coordination mechanism 
across concerned sectors
(( No clear national criteria to declare the 
cholera outbreak
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Opportunities and Threats 
Opportunities Threats
Surveillance (( EWARS system is already in 
place in all 75 districts
(( There is room and political will 
to expand this system
(( External agencies are ready to 
help in strengthening existing 
surveillance system
(( Health system of the defense 
sector could be included in 
EWARS
(( Continued poor surveillance 
making it impossible to accurately 
determine disease burden in the 
country (only 50% of sentinel sites 
are functional)
(( Manpower restrictions could limit 
the EDCDs ability to follow-up 
with hospitals if the system were 
expanded
(( Lack of motivation, dedication and 
will power from staff working in 
surveillance system




(( Successful use of the Rapid 
Diagnostic Test for cholera in 
the Kathmandu Valley, with the 
potential for expansion to other 
areas of the country
(( Simple training on RDT 
procedure for health staff 
working in periphery 
(( Lack of adequately equipped labs 
around the country capable of 
diagnosing cholera on site
(( No dedicated budget for purchase 
of RDTs  
Field 
Investigation
(( Rapid Response Teams are a 
built-in resource of the EWARS 
system and has been expanded 
during the 2016 cholera season 
in Kathmandu
(( Inclusion of Response Team from 
the defense sector, volunteers 
and private organizations in 
emergency situations
(( Lack of funding to support the 
expansion of RRTs may limit their 
ability to respond to every cholera 
case
(( Denial by some patients to participate 
in household investigation due to 
lack of knowledge and/or stigma
(( Loss to follow-up due to movement
(( Difficulties identifying actual 




(( Routine monitoring of antibiotic 
resistance means changes 
can be made to treatment 
recommendations during an 
outbreak if necessary
(( Limited supply of needed medical 
supplies (such as IV fluids) in rural 
health facilities
(( Frequent stock outs of medicines 
and supplies






(( At home, point of use 
disinfectant products are 
available in markets and can 
be a major message of health 
information campaigns in at-
risk areas
(( Protection of source of drinking 
water by DWSS
(( Many households use standard 
size black water tanks which 
could make interventions at 
these households much easier 
(e.g. correct concentration of 
chlorine)
(( The cost of these materials is not 
regulated, and could be a major 
factor in a household decision to 
use chlorination at home
(( Limited availability of hand washing 
stations in the home
Cholera 
Vaccination
(( Increasing availability of OCV in 
the market, making it easier to 
apply to the global stockpile
(( Global supply of OCV is limited 
(( Due to lack of funds for direct 
purchase, the government must 
rely on donations or successful 





for Safe WASH 
Practices
(( Strong partnerships with 
organizations such as UNICEF 
means many opportunities 
to refine materials as new 
information becomes available 
in Nepal and globally
(( Interest by donors in conducting 
operations research to obtain 
data on effectiveness of WASH 
strategies
(( Not much data exists on the 
effectiveness of WASH and behavior 





(( Recent interest of donor 
organizations in the control 
of cholera in Nepal due to the 
2015 earthquakes and their 
commitment to support the 
EDCD in their response and 
control efforts
(( Increasing attention to cholera 
control by the government due 
to 2016 outbreak and response
(( No mechanism for an ‘emergency’ 
response, which bypasses the 
typical approval pathways for rapid 
interventions at the household and 
community level
(( No clear cut mechanism for multi-
sectoral coordination
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3. Preparedness and Response Plan
This Preparedness and Response Plan 
details the actions necessary to strengthen 
the existing surveillance of and response to 
cholera outbreaks. It describes a series of 
strategies to reduce the risk of transmission 
of and mortality due to Vibrio cholerae.
3.1 Main Objective
Improve the overall health status of 
the Nepali population by reducing the 
incidence of cholera and eliminate 
cholera deaths in Nepal. 
3.2 Specific Objectives
1. To prevent the spread of AGE/Cholera
2. To eliminate mortality from AGE/Cholera
3. To ensure coordinated and collaborative 
AGE/Cholera preparedness and response
4. To ensure a rapid response mechanism 
during an outbreak of AGE/Cholera
3.3 Strategies for Preparedness and Response
(1) Prevent spread of AGE/Cholera outbreaks
(1.1) Surveillance and early warning
Hospital Reporting
Passive, hospital-based surveillance of 
suspected cases of epidemic-prone diseases 
is being instituted as per standard protocol at 
all district/Zonal/ regional/central hospitals, 
which serve as sentinel sites under the Early 
Warning and Response System (EWARS). 
Each hospital will report the diarrhea cases 
registered at emergency and OPD departments 
to their District (Public) Health Offices and 
the EWARS focal point at EDCD.  In case of 
an epidemic, daily reporting will be done by 
phone. D(P)HO staff will visit the emergency 
and OPD departments and collect aggregated 
information on a standardized form (Annex 1). 
Rumor verification and data monitoring will 
also take place at district level. Data will be 
reported from the D(P)HO to the central level 
(HMIS); reports from each emergency and 
OPD department will be consolidated into a 
central database (EWARS). Reporting from 
the EWARS sentinel sites will be monitored 
closely by the EDCD surveillance team to 
ensure that it is accurate and timely. 
In an outbreak situation, EWARS should 
be expanded to additional health facilities 
beyond designated sentinel sites. The 
expansion sites should be decided upon 
before the monsoon season and districts 
should have a plan for the expansion at least 
one month prior. 
Female Community Health Volunteers 
working in the districts should be oriented on 
reporting deaths from AWD in the community 
that may not have been treated at a health 
facility to the DPHO. These messages should 
be continued throughout the monsoon season 
and be increased in the event of an outbreak 
in the district or a neighboring district.
Laboratory Surveillance
Rapid Diagnostic Tests (RDT) will be used 
as point of care diagnosis at the health 
facility level. Each district will be provided 
a stockpile of RDTs to distribute to the 
appropriate facilities as needed. These 
stockpiles will be prepared prior to the 
beginning of the cholera season. Methods on 
how to preform the rapid test are available in 
Annex 2. If culture facilities are not available 
in the health facility or district level facilities, 
samples will be collected and stored in Cary 
Blair Transport Media and transported to the 
National Public Health Laboratory (NPHL) 
as soon as possible for confirmation. No less 
than 10% of cases should be confirmed at 
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the hospital or national level. In the event 
that transport media is not available, stool 
samples can also be stored on filter paper 
and sent to the National Lab for confirmation 
by PCR or other molecular studies (methods 
for sample collection on filter paper can be 
found in Annex 2). All Laboratory results at 
the health facility or district level facilities 
should be reported to EWARS as well as the 
NPHL.
Antibiotic Resistance
In order to provide the best care possible to 
cholera patients, antibiotic resistance will 
be monitored. Any facility that performs 
cholera culture, whether it be hospital lab 
or NPHL, should test samples positive for 
cholera for antibiotic resistance. This should 
be conducted for up to 10 positive samples 
every two weeks throughout the outbreak. 
These results should be sent to EDCD as part 
of regular cholera surveillance reporting. In 
the event that a new resistance pattern is seen 
and national antibiotic recommendations 
need to be updated, the EDCD will handle 
the dissemination.
Assessments
Annual assessments of laboratory capacity 
and training of staff will take place at the 
district level. DPHOs will report to the NPHL 
whether their district has the capacity for 
culturing cholera and whether they have 
culture materials (TCBS and antisera), 
transport media, filter paper, and RDTs in 
stock. Reporting on stocks will take place 
monthly. Resources will be sent to these 
districts to full-fill their needs as necessary 
prior to the cholera season. Stocks will 
be replenished throughout the season as 
necessary. Coordination meetings with 
surveillance stakeholders will take place 
throughout the season. 
Reporting 
Situation reports will be published weekly by 
EDCD. This will be increased to daily during 
an outbreak. An alert will be issued and 
investigated as potential cholera by EDCD 
in the event of an adult death with AWD, 
or a cluster (>3 cases) of AWD with severe 
dehydration.
Key Activities for Surveillance and Early 
Warning
Plan for the expansion of EWARS and 
ensure it is functional in all its current 
facilities / sentinel sites
Provide a list of sites for expansion of 
EWARS for each district in case an outbreak 
occurs 
Coordinate meetings with appropriate NGOs 
and other partners in surveillance efforts
Conduct training for health facility staff (at 
minimum annually) at the community and 
district levels regarding surveillance, case 
definition, data flow, and outbreak response
Establish outbreak response, rumor 
verification, and monitoring of data at 
district level
Orient FCHVs on identifying potential 
cholera cases and deaths in the community
Publish and disseminate weekly (daily 
during an outbreak) updates via AGE/
Cholera Situation Reports 
Conduct laboratory capacity assessments 
and distribute RDTs to all DPHOs for 
confirmation of cases at all levels of the 
health care delivery system
(1.2) Water, Sanitation and Hygiene (WASH)
Community Level WASH Interventions
Preventive water, sanitation and hygiene 
(WASH) interventions will be specifically 
targeted to the household, community 
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including food vendors, school, work-place 
and health facility levels.  The following list 
of interventions will be stockpiled at the 
national level for deployment to districts in 
need throughout the cholera season: Piyush, 
aquatabs, soap, hygiene kits, and educational 
posters and pamphlets. 
Specific WASH activities will take place prior 
to the cholera season in high-risk areas in 
each district. These include standardized 
radio messaging on health behaviors and 
in-person messaging campaigns in any 
internal displacement camps. The DPHO will 
also be responsible for ensuring that water 
treatment, such as aquatabs, are available 
locally prior to the season, and that solid 
waste is handled appropriately. DPHO will 
also encourage construction of household 
toilets and hand washing facilities and/or 
adequate maintenance. 
Water Supply Interventions
Specific interventions concerning access to 
drinking water will be established by performing 
routine analysis of the existing water supply 
infrastructure, storage, and distribution 
network. Water supply stakeholders will 
be invited as key members of the Steering 
Committee for Enteric Diseases to provide 
reports on the system prior to the monsoon 
season. The Department of Water Supply and 
Sanitation (DWSS) and its district offices will 
be engaged to provide routine water quality 
monitoring in the form of free residual chlorine 
and fecal coliform tests. Any drinking water 
sources found to be unfit for drinking will be 
followed up on by the MOH. Resources will be 
provided to the DWSS laboratory for culturing 
of Vibrio cholera. If any source is found to 
contain Vibrio cholerae, the DPHO will deploy 
individuals to ensure the source is not used by 
the public until the issue is solved. Any source 
found positive for V. cholerae by the DWSS, 
will be confirmed by NPHL.
Key Activities for WASH Response
Chlorinate all piped drinking water systems 
and water tankers
Regularly monitor systems prior to the season 
and more frequently during outbreaks, 
including provision of chlorination materials 
and training where required
Train on point of use drinking water 
treatment at the household level in high 
risk areas
Implement a food safety campaign targeting 
both food vendors and households through 
social mobilization and mass media 
channels 
Practice hand-washing with soap through 
health messaging campaigns at critical 
times
Ensure proper collection and management 
of solid waste 
Support community led sanitation activities 
to encourage households and health posts 
to rebuild/build toilets and hand-washing 
facilities
Maintain adequate sanitation and hand-
washing facilities in households 
Pre-position WASH materials at the 
local level to enable rapid scale-up of 
interventions in new areas, and continuity 
in existing areas, in the event of an outbreak
Stockpile adequate WASH equipment 
and ensure materials are available in 
Kathmandu to be deployed when necessary
(1.3) Immunization with oral cholera vaccine 
       (OCV)
OCV Strategy
Oral cholera vaccines (OCV) are safe, 
effective, and acceptable.  They present a 
tool for cholera control that supplements, 
but vaccine does not replace, existing 
cholera control measures such as WASH 
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interventions.  Three WHO pre-qualified oral 
cholera vaccines are available through the 
Global Stockpile; two are available for direct 
purchase. 
Vaccination of populations can either be 
pre-emptive, before the cholera season in 
evidence-based, pre-determined hot-spot 
areas, or as a reactive action during an outbreak 
in order to limit and reduce spread of the 
disease.  Reactive vaccination may be carried 
out in an area at risk for cholera and adjacent 
to an area with ongoing transmission.  Due to 
the limited amount of vaccine available in the 
country at this time and limited availability of 
data on which to base targeting of pre-emptive 
vaccination, a reactive approach is favored for 
the country at this time.
Vaccination will be used for:  
l(Prevention of potential cholera outbreaks 
where essential services to prevent the 
spread of Vibrio cholerae in the environment 
(adequate clean water, sanitation and 
hygiene) and health care are disrupted or 
destroyed, mobile populations residing in 
crowded settings, or areas at high-risk for 
cholera outbreaks. Any pre-emptive OCV 
campaign should be conducted at least two 
months prior to the monsoon season with 
two doses administered two weeks apart. 
l(Reducing the spread of cholera and limiting 
mortality in communities neighboring a 
current outbreak (communities across 
borders or linked by river systems or 
water and sanitation systems). A reactive 
vaccination strategy (vaccination within a 
100-meter radius around an index cases) 
can be applied in outbreak situations with 
a single dose of OCV. 
If possible, a stockpile of vaccine will be 
created at the national level (ideally, 50,000 
doses). This stockpile would be in place prior 
to the monsoon season and provide doses for 
reactive vaccination. This stockpile would 
be replenished as the vaccine was used, 
and could also provide a buffer in the event 
more vaccine needs to be obtained for larger 
outbreaks,
Planning
Detailed micro-planning will take place 
at the periphery level. Training will be 
conducted for FCHVs and health workers 
prior to the start of the season, and 
refresher trainings will take place as 
needed. Standard forms will be available 
in each district. Media will be oriented 
to the use of the OCV to ensure that a 
positive message is sent to the public. 
Radio messaging will also take place at the 
district level to ensure the population has 
access to accurate information on when/
where/why campaigns are taking place.
Reporting
Vaccination teams must also use tally sheets 
(Annex 3) to record the number of people 
vaccinated per day, at each vaccination 
site by each team. FCHVs will monitor the 
population for any adverse events post-
vaccination and report results to the district 
level using a standard form (Annex 4). Number 
of new cases that appear in the vaccinated 
area will also be reported for analysis at the 
national level.
Incorporation of Health Education 
OCV should not be used as a stand -alone 
intervention. Integrated information, 
education and communication materials will 
be distributed along with vaccine and will be 
available in each district prior to the season 
(Annex 5). 
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Key Activities for Immunization
Select areas for pre-emptive vaccination if 
adequate information is available to support 
a hot-spot or hot-pop
Ensure a stockpile of vaccine is in place 
prior to the beginning of monsoon season
Distribute integrated information, 
education, and communication (IEC) 
materials for OCV and safe hygiene 
practices, (i.e. hand washing with soap)
Develop a detailed micro-plan for vaccine 
delivery and ensure it is available and 
understood at the periphery level
Conduct training for FCHVs and health 
workers on OCV and hygiene promotion
Ensure availability of guidelines, forms, 
and IEC materials for OCV campaigns at 
the district level
Conduct media orientation (at both central 
and district levels) to mitigate rumor/
negative coverage of OCV campaigns 
Air radio/FM messages on OCV campaigns 
using district level radio stations
Ensure proper documentation and 
monitoring and evaluation of cholera 
campaigns by providing standard materials 
to each DPHO
(1.4) Behavior Change Communication (BCC)    
         and Social Mobilization
Extensive community mobilization and 
behavior change communication activities 
are required to prevent and mitigate AGE/
cholera by encouraging safe hygiene 
practices. Existing networks of partner NGOs 
and FCHVs in affected districts work with 
district (public) health offices to come up 
with a detailed activity plan and will then 
be mobilized to disseminate key messages 
and orient households at community 
level prior to the cholera season.  During 
the cholera season, FCHVs, as the hub 
of community mobilization, will be given 
simple communication guideline and then 
activated to deliver regular interpersonal 
communication sessions on key health/WASH 
behaviors, as well as distribute essential 
health/WASH items such as ORS, zinc, 
and soap to hot-spots and hot-pops in their 
district. WASH promotion will also take place 
during the season at schools and community 
gatherings.
Key Activities for BCC and Social Mobilization 
Develop a detailed activity plan and align 
with other stakeholders working in health 
and WASH sectors at the district level
Involve NGO partners working in health and 
WASH and support them in their promotion 
of safe hygiene practices 
Orient teachers and school children on 
WASH 
Promote WASH through door to door 
mobilization of FCHVs in the community 
Distribute simple communication 
guidelines on key hygiene behaviors, case 
detection, and referral to community-level 
social mobilizers (identified by DPHOs)
Promote key health behaviors during 
community gatherings 
(1.5) Community Level Interventions
Community-based interventions for health, 
nutrition and WASH can be integrated and 
promoted into all community-based activities 
in a variety of sectors through community-
based actors to target greater outreach to 
the communities. The following interventions 
will be planned:
q(Health and hygiene promotion 
(distribution of brochures)
q(Water testing 
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q(Distribution of soap and Piyush at high 
risk areas
q(Miking in high-risk areas
q(Active case finding and early detection 
by FCHVs, including referral to health 
facilities
q(Communication on use of household 
water treatment and ORS at home
Key Activities at the Community Level 
Identify all actors to deliver integrated 
services: community health workers, village 
health workers, hygiene promoters, social 
mobilisers, traditional birth attendants, 
Red Cross volunteers etc.
Conduct training for community level 
actors in health education and hygiene 
promotion, active case finding, early 
case detection, use of household water 
treatment and ORS at home, and referral 
to health facilities
Distribute IEC materials for safe hygiene 
practices, household water treatment, and 
messages on when to start home treatment 
with ORS and/or to seek immediate 
treatment to the community
(2) Reduce the mortality from AGE/cholera
(2.1) Standardized Case Management
Assessment
Capacity building for identification, case 
management, reporting, referral, and 
infection control in health care settings will 
take place in all levels of health facilities 
annually.  EDCD will coordinate capacity 
building activities to avoid duplication and 
ensure that critical gaps are filled prior to the 
cholera season. The EDCD will work to provide 
a digital resource center where stakeholders 
can access forms, guidelines, dehydration 
algorithms and other materials.  
Treatment of Cholera Cases 
Cholera is an easily treatable disease. 
Treatment centers around rehydration. The 
prompt administration of oral rehydration 
salts to replace lost fluids (5ml/kg/hour) 
nearly always results in the patient being 
cured. All district level health facilities will be 
activated and medical officers will be trained 
for treatment prior to the start of the cholera 
season. In cases of severe dehydration or 
hypovolemic shock due to diarrhea (Table 2), 
intravenous administration of fluids (Ringers 
Lactate; Table 3) may be required to save 
the patient’s life. These patients should 
be monitored every 30 minutes. After the 
first 30ml/kg of fluids have been given the 
patient’s radial pulse should be strong and 
the patient’s blood pressure should return 
to normal. If the pulse is not strong, IV 
fluid administration should be continued. 
Adults should be reassessed after 3 hours 
and infants after 6 hours of receiving fluids 
and start ORS (about 5 ml/kg/hr) as soon as 
patient can drink safely.
Table 2: Assessment of Dehydration
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Table 3: Estimation of Ringers Lactate IV for 
patients with Severe Dehydration






1 hour 5 hours
1 year and over 30 minutes 2.5 hours
Antibiotics should be given to any patient 
with cholera who comes for treatment 
and the preferred antibiotic is doxycycline 
(currently circulating strain must be checked 
for resistance). In the case of resistance to 
doxycycline, azithromycin should be used.
Azithromycin should also be used for pregnant 
women and children under eight years. By 
decreasing the duration of diarrhea and stool 
volume, antibiotic use will result in more rapid 
recovery and shorter lengths of inpatient stay, 
both of which contribute to optimizing resource 
utilization in an outbreak setting. Hydration 
kits will be deployed to District Public Health 
Offices for their EWARS sentinel sites well 
before the typical cholera season, and will be 
replenished immediately upon use.
For more detailed information on cholera 
treatment guidelines please refer to the WHO’s 
“The Treatment of Diarrhoea: A manual for 
physicians and other senior health workers.” 
This document was last revised in 2005 and 
is available online.
Discharge of Cholera Patients
Suspected cholera patients should remain at 
the health facility until diarrhea and vomiting 
have stopped (expected within 24 hours). 
Even after dehydration is corrected, additional 
fluids may be needed to compensate for 
ongoing fluid losses. The patient should be 
told to return to the health facility if they 
experience an increased number of stools, 
loss of appetite, excessive thirst, repeated 
vomiting, fever, or blood in stool.
Key Activities for Case Management 
Annual Training of Trainers (TOT) for AGE/
Cholera management and subsequent 
training of health workers 
Monitor training activities at the district 
level 
Create a Digital Resource Center accessible 
to all districts and partners through the 
EDCD 
Support supervision, monitoring visits, and 
quality assurance through standardized 
practices
Distribute case management guidelines 
and algorithms for assessing dehydration 
and managing patients, including the 
identification and management of 
dehydration for malnourished children
(2.2) Supplies and Logistics
Stockpile
Medical supplies including Interagency 
Diarrheal Disease Kits (IDDKs), additional 
ORS, antibiotics, and other supplies will be 
strategically pre-positioned by EDCD, WHO 
and UNICEF at the regional level. There 
will be an additional stockpile of IDDKs in 
Kathmandu.
Distribution
Regular tracking and monitoring will take 
place and each region will receive supplies 
based on the number of EWARS sentinel sites 
and expansion sites in that region. Supplies 
will be distributed no later than one month 
prior to the monsoon season. Additional 
supplies will be sent from the national 
stockpile in Kathmandu as necessary during 
outbreak situations.
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Key Activities for Supplies and Logistics 
Map necessary supplies annually to address 
current needs, including a distribution plan
Procure additional supplies as needed for 
agreed minimum level preparedness
Ensure timely distribution of available 
supplies based on need and risk in affected 
areas
Regularly track and monitor inventory and 
replenish supplies as needed 
(3) Coordination and Collaboration Surrounding 
      Cholera Preparedness and Response
Steering Committee for Enteric Diseases and 
Task Force for Cholera Control
The Epidemiology and Disease Control 
Division of the Department of Health Services 
(EDCD) will take the lead and provide 
overall coordination and collaboration of 
AGE/cholera prevention, preparedness, and 
response activities. They will disseminate 
timely surveillance information through an 
AGE/cholera Situation Report to enable rapid 
response by all stakeholders. The existing 
high-level Steering Committee for Control 
of Enteric Diseases will guide the decision 
making for the control of enteric diseases 
in Nepal and meet one moth prior to each 
monsoon season to discuss plans for cholera 
preparedness and response. This committee 
will also ensure that all districts have the 
necessary resources and are aware of reporting 
mandates. The Task Force for Cholera Control, 
a sub-committee of the abovementioned 
Steering Committee is chaired by Director 
of EDCD and includes representation from 
the WASH cluster, WHO, UNICEF, GTA, 
and relevant INGOs/NGOs in addition to 
the Ministry of Health (MoH). They will be 
responsible for mapping available resources 
to identify gaps prior to the season. It will be 
responsible to ensuring any decisions from 
the Steering Committee are implemented 
accordingly. The task force will meet at 
least monthly during the monsoon season to 
monitor the response and to ensure a solid 
and well-coordinated response mechanism 
for immediate action. The task force will 
monitor progress of outbreaks and review 
the prevention, preparedness and response 
plan on a yearly basis to adjust to prevailing 
situation, and will tailor the response more 
frequently during an outbreak if absolutely 
necessary.
Situation Reports
As a means of rapidly disseminating 
information on the current cholera situation 
to all interested parties, the EDCD will publish 
a weekly situation report during the monsoon 
season detailing AGE and cholera cases. 
This report will include information on both 
suspected and confirmed cases, and include 
the number of cases reported by each EWARS 
sentinel site. A map detailing the geographic 
distribution of cases will also be included in 
the report to assist in developing response 
activities. An example of the Situation Report 
can be found in Annex 6. In the event of an 
outbreak situation, this report will be updated 
and distributed on a daily basis.
Key Activities for Coordination and 
Collaboration 
Map available resources and existing gaps 
(funds, supplies, partner contact details, 
response plans etc.) prior to the season to 
ensure preparedness
Conduct regular meetings of the Task force 
for Cholera Control to obtain updates on 
the AGE/cholera situation, surveillance 
and control operations, status of essential 
supplies, and gaps in resources
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Key Activities for Coordination and 
Collaboration, continued
Share information through a weekly AGE/
Cholera Situation Report sent by email 
from EDCD with a summary of the current 
AGE/Cholera numbers (daily in the case of 
an outbreak)
Discuss possible field level (district and 
below) coordination and collaboration of 
response through the government health 
system and other stakeholders to ensure a 
response can take place as soon as possible
(4) Rapid Response Mechanism
Cholera has the ability to spread quickly, 
particularly when a contaminated drinking 
water source is used by a large population. 
Therefore, it is essential that the government 
response takes place as soon as possible, 
and preferably, within 24 hours of a case 
being reported. Investigations should be 
conducted whenever a single case meets 
the clinical definition since the illness is 
likely to be more widespread than a single 
case (given the majority of cholera cases are 
mild or asymptomatic). Previous experience 
has shown that implementing interventions 
such as a WASH or vaccination campaign 
in response to a case of cholera under the 
current system can take weeks. Therefore, a 
mechanism will be put in place within the 
existing government system to ensure the 
response activities outlined in the national 
plan can be initiated within this critical 
48-hour window. A government official 
will be selected who has the authority and 
responsibility to give the “green light” 
for implementation of community level 
campaigns to control cholera. Districts should 
have agreed upon action plans for such 
campaigns at least two months prior to the 
start of the season to avoid delays. Stockpiles 
of necessary supplies at the district, regional, 
and national levels will be utilized to carry 
out the response. Plans will be made at the 
district level for when/where supplies will 
be retrieved and who will be responsible for 
delivering them.  
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Rapid Response Teams
Rapid Response Teams (RRT) should be 
formed at the central, regional, and district 
levels. These teams will be trained annually 
and be on stand-by during the monsoon 
season to conduct field investigations, deliver 
interventions, and ensure stool specimens are 
send to the lab for confirmation. At the central 
level, the Director of EDCD will serve as the 
chair, the Chief of the Epidemiology Section 
will be the focal point, and membership will 
also contain representatives from the National 
Public Health Laboratory, Child Health 
Division, Logistic Management Division and 
other sections of EDCD. The Regional Director 
will be the focal point for regional level RRT 
and the other members will include a medical 
officer, a malaria/public health officer, a 
health assistant, a health education officer, a 
statistics officer, the immunization supervisor, 
a lab technician and a public health nurse. The 
district level RRT will be chaired by the Chief 
of the DPHO, with a health assistant from the 
DPHO as the focal point. Other members of the 
district level RRT will include the immunization 
supervisor, a health education technician, a 
medical officer, a public health nurse, a lab 
technician, a statistician, a medical recorder 
and a family planning assistant.(29) 
When RRTs are mobilized, the field team should 
consist of at least one public health/clinical 
officer, one lab technician, and one health 
educator. FCHVs from the municipalities/VDCs 
can be included as necessary, dependent upon 
the size of the outbreak. The duties of the rapid 
response team are to: 
l(Verify reported cases 
l(Investigate new cases 
l(Obtain lab specimens for confirmation
l(Identify hot-populations (high-risk groups)
l(Investigate water source contamination
l(Assess local capacity to respond (case 
management and community control 
measures)
l(Implement control measures (including 
WASH and OCV)
l(Provide emergency treatment and supplies
l(Collect line listing of information on 
cases for analysis
l(Report findings to EDCD
Line Listing and Risk Factor Collection
A line listing should be made available to 
rapid response teams by EWARS sentinel 
sites in order to identify cases for household 
investigation. It is essential that this line 
listing include identifying information for 
the patient (name, age, address, telephone 
number). For each case, the rapid response 
team should collect and analyze data on the 
following risk factors:
l(Recent travel history 
l(Contact with persons with diarrhea
l(Recent attendance at a crowded event
l(Water sources for drinking, bathing, 
and cleaning kitchen utensils
l(Food history (consuming raw fruits, 
vegetables or juices, eating room-
temperature food)
l(Occupation
An example of a risk factor data collection 
form can be found in Annex 7.
Key Activities for a Rapid Response
Designate a government official responsible for 
emergency implementation of response activities
Prepare district level plans for the conduct of 
community level WASH and reactive vaccination 
campaigns at least two months prior to the 
monsoon season
Map where supplies will be retrieved and who 
will deliver them for rapid implementation of the 
cholera response
Train RRTs annually on response activities 
Collect and analyze data from the line listings 
and household investigations of all cholera cases
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4. Plan of Action 








1 Surveillance and Early Warning Activities
i Plan for the expansion of EWARS 
and ensure it is functional in all 




ii Provide a list of sites for expansion 
of EWARS for each district in 
case an outbreak occurs
EDCD/DPHO/Health 
Facilities
iii Coordinate meetings with 
appropriate NGOs and other 
partners in surveillance efforts
EDCD/DPHO/I/NGO 
partners
iv Conduct training for health 
facility staff (at minimum 
annually) at the community 
and district levels regarding 
surveillance, case definition, 
data flow, and outbreak response
EDCD/DPHO/I/NGO 
partners
v Orient FCHVs on identifying 
potential cholera cases and 
deaths in the community
DPHO/ Health Facilities
vi Establish outbreak response, 
rumor verification, and monitoring 
of data at district level
EDCD/DPHO
vii Publish and disseminate weekly 
(daily during an outbreak) updates 
via AGE/Cholera Situation Reports 
EDCD
viii Conduct laboratory capacity 
assessments and distribute RDTs 
to all DPHOs for confirmation of 





i Chlorinate all piped drinking 
water systems and water tankers
DWSS/Water vendors/I/
NGO partners
ii Regularly monitor systems 
prior to the season and more 
frequently during outbreaks, 
including provision of 
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iii Train on point of use drinking 
water treatment at the household 
level in high risk areas
DPHO/WSSDO/
Community People
iv Implement a food safety 
campaign targeting both food 
vendors and households through 





v Practice hand-washing with 
soap through health messaging 




vi Ensure proper collection and 
management of solid waste 
Municipality/Private 
sectors/I/NGOs
vii Support community led 
sanitation activities to encourage 
households and health posts to 





viii Maintain adequate sanitation 





ix Pre-position WASH materials at 
the local level to enable rapid 
scale-up of interventions in 
new areas, and continuity in 




x Stockpile adequate WASH 
equipment and materials are 





i Select areas for pre-emptive 
vaccination if adequate 
information is available to 




ii Ensure a stockpile of vaccine is 
in place prior to the beginning 
of monsoon season
EDCD/CHD/LMD
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iii Distribute integrated 
information, education, and 
communication (IEC) materials 
for OCV and safe hygiene 





iv Develop a detailed micro-plan 
for vaccine delivery and ensure 





v Conduct training for FCHVs 





vi Ensure availability of guidelines, 
forms, and IEC materials for OCV 
campaigns at the district level
EDCD/CHD/DPHO/I/
NGO partners
vii Conduct media orientation (at 
both central and district levels) 
to mitigate rumor/negative 
coverage of OCV campaigns 
EDCD/DPHO/I/NGO 
partners
viii Air radio/FM messages on OCV 




ix Ensure proper documentation 
and monitoring and evaluation 
(M&E) of cholera campaigns by 




4 Social Mobilization Activities
i Develop a detailed activity plan 
and align with other stakeholders 
working in health and WASH 
sectors at the district level
DWSS/EDCD/DPHO/
WSSDO/I/NGO partners
ii Involve NGO partners working in 
health and WASH and support 




iii Orient teachers and school 
children on WASH 
EDCD/DPHO/WSSDO/
VDC/NGO partners
iv Promote WASH through door to 
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v Distribute simple 
communication guidelines 
on key hygiene behaviors, 
case detection, and referral 
to community-level social 





vi Promote key health behaviors 




5 Community Level Activities
i Identify all actors to deliver 
integrated services: community 
health workers, village health 
workers, hygiene promoters, 
social mobilisers, traditional 





ii Conduct training for community 
level actors in health education 
and hygiene promotion, 
active case finding, early case 
detection, use of household 
water treatment and ORS at 






iii Distribute IEC materials 
for safe hygiene practices, 
household water treatment, 
and messages on when to start 
home treatment with ORS and/






6 Case Management Activities
i Annual Training of Trainers 
(TOT) for AGE/Cholera 
management and subsequent 
training of health workers 
EDCD/DPHO/I/NGO 
partners
ii Monitor training activities at the 
district level 
EDCD/DPHO
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iii Create a Digital Resource 
Center accessible to all districts 
and partners through the EDCD 
EDCD/DPHO/I/NGO 
partners
iv Support supervision, monitoring 




v Distribute case management 
guidelines and algorithms 
for assessing dehydration 
and managing patients, 
including the identification and 





7 Supplies and Logistics Activities
i Map necessary supplies 
annually to address current 
needs, including a distribution 
plan
EDCD/LMD/DPHO/ 
Local Health Facilities /
NGO partners
ii Procure additional supplies as 




iii Ensure timely distribution of 
available supplies based on 
need and risk in affected areas
EDCD/LMD/DPHO/I/
NGO partners
iv Regularly track and monitor 
inventory and replenish supplies 
as needed 
EDCD/LMD/DPHO
8 Coordination and Collaboration Activities
i Map available resources and 
existing gaps (funds, supplies, 
partner contact details, 
response plans etc.) prior to the 




ii Conduct regular meetings of the 
Task force for Cholera Control 
to obtain updates on the AGE/
cholera situation, surveillance 
and control operations, status 
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Iii Share information through a 
weekly AGE/Cholera Situation 
Report sent by email from EDCD 
with a summary of the current 
AGE/Cholera numbers (daily in 




Iv Discuss possible field level 
(district and below) coordination 
and collaboration of response 
through the government health 
system and other stakeholders 
to ensure a response can take 
place as soon as possible
DPHO/I/NGO partners
9 Rapid Response Activities
i Designate a government official 
responsible for emergency 




ii Prepare district level plans for 
the conduct of community level 
WASH and reactive vaccination 
campaigns at least two months 




iii Map where supplies will be 
retrieved and who will deliver 
them for rapid implementation 








v Collect and analyze data from 
the line listings and household 
investigations of all cholera 
cases
EDCD/DPHO
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5. Monitoring and Evaluation of 
    Surveillance and Response 
Conducting routine monitoring and evaluation 
is important in ensuring an effective and 
efficient surveillance and response system 
year after year (WHO). Monitoring and 
evaluation of the successful implementation 
of this plan will be led by EDCD at the 
EWARS sentinel sites and by the DPHOs in 
coordination with EDCD at periphery level 
health facilities.   
According to the WHO Guide to Monitoring 
and Evaluation of Communicable Disease 
Surveillance and Response Systems, 
monitoring in this context refers to “the 
routine and continuous tracking of the 
implementation of planned surveillance 
activities and of the overall performance 
of surveillance and response systems,” 
and evaluation refers to the “periodic 
assessment of the relevance, effectiveness 
and impact of activities” based on the 
objectives set forth for those activities.
(30) These activities must be implemented 
in a manner that allows for adjustment of 
the plan on an annual basis. The Steering 
Committee for Enteric Diseases, chaired 
by the Director of the EDCD, will review 
the results of this evaluation during their 
post-monsoon session and recommend any 
necessary revisions to the plan.
Indicators
A series of indicators have been outlined in 
Annex 8 and are specified for surveillance, 
response, and laboratory activities. The 
EDCD is responsible for collecting data on 
these indicators and analyzing results for 
dissemination to the Steering Committee. 
Explanations of results as well as specific 
recommendations should be provided. 
Timing the evaluations
Evaluations will take place annually during 
the post-monsoon season after cases have 
subsided. However, the Task Force for 
Cholera Control should also perform interim 
evaluations may be performed to track 
progress determine whether the program is 
on target with the goals outlined in this plan 
and to implement changes if needed. This 
will be particularly important for monitoring 
stockpiles of supplies throughout the season. 
It will also ensure that stakeholders can 
be held responsible for their activities as 
outlined in the plan of action. 
Key Activities for Monitoring and Evaluation 
Track progress of implementation of 
planned activities
Identify problems in the system in order to 
institute corrective measures in a timely 
manner
Track stocks of key resources to avoid delays 
in response 
Ensure that all parties are held responsible 
and accountable for their defined activities 
as outlined in the Plan of Action
Collect and analyze data on the outlined 
indicators 
Disseminate results to the Steering 
Committee 
Provide explanations for achievements and 
failures in the system
Provide specific recommendations for 
improving the system
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ANNEX 1b: Variable Definitions
Variable Name Description Codes
Hospital Name of the hospital Text
Patient ID Registration number of the patients or 
if not available registration number as 
specified in the ER registers 
Num
Name of Patient Name of the patient Text
Age age of the patient Num
Sex sex of the patient M/F
Phone Phone number (mobile) of the patient Num
Name of Guardian Name of the father or mother or relatives Text
Date of Admission Date of admission in ER or OPD or date 
of registration in wards
Date
OPD/Eme/IPD Please select type of patient registration 
(OPD/IPD/Emergency).
OPD, EME, IPD
District District of current residence Coded values
VDC VDC of current residence VDC codes
Ward Number of the ward of the current 
residence
Num
VillageOrTole Name of the Village or Tole Text
ProvisionalDiagnosis Provisional diagnosis during admission AWD (Acute 
Watery Diarrhoea) ; 
SC(Suspected cholera)
StoolCollected Was a stool sample collected in 
admission?
Y/N
Outcome Outcome of the disease at discharge 1. Treatment; 
2.cured;2.referred;3.
death;4.Unk
RDT Was an RDT for cholera performed? Y/N
Culture Was culture performed Y/N
ResultRDT Result of cholera RDT Positive/Negative
ResultCulture Result of Culture for cholera at hospital Positive/Negative
DateLabResult Date it was tested in the laboratory of 
the hospital
Date
DateResultNPHL Date it was tested in NPHL Date
Sample sent to NPHL (Y/N) Was the sample sent to NPHL? Y/N
DateSentNPHL The date the sample was sent to NPHL date
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ANNEX 2: Methods for Using the Rapid 
Diagnostic Test with Enrichment Step
Fecal Specimen Collection Procedure
1 For collection of fecal specimens, the 
laboratory technician must collect 
a recently discharged or fresh stool 
sample from the patient. Prepare 
necessary supplies including labeled 
stool container, gloves, plastic spoon, 
and 2 plastic bags at the time of 
presentation. Use the plastic spoon to 
collect 3-4 spoons of stool and place it 
in the labeled stool container properly. 
If the stool is watery, use container 
directly to collect approximately 5 ml 
of stool. 
2 If a diarrheal stool sample is not 
available, the health facility clinical 
staff should collect a rectal swab. 
To collect a rectal swab, take verbal 
consent, insert swab 1-1.5 inches into 
the rectum and gently rotate. The swab 
should be visibly stained with stool. 
Then insert the swab deep into a tube 
of APW, break off the tip, and close the 
cap.
Enriched Cholera RDT 
1 Ensure appropriate PPE is worn by 
health facility staff processing the 
specimens.
2 Immediately upon receipt of the fecal 
specimen, dip a cotton-tipped wooden 
stick in the fecal specimen and place 
in APW media for 6 hours (minimum of 
5 to a maximum of 18 hours). 
  APW must be inoculated on the day of 
fecal specimen collection OR Cary-Blaire 
must be inoculated from the original 
specimen.
3 Using a pipette, collect a small amount 
of specimen-enriched APW from the 
top of the APW tube. Do not shake the 
APW tube prior to collection. Add 2-4 
drops of the specimen-enriched APW 
into kit’s test tube.  
4 Place a Crystal VC dipstick into the test 
tube and wait for exactly 15 minutes 
(do not exceed 15 minutes). 
5 Read the dipstick at 15 minutes, 
verifying that the positive control 
band is visible to ensure quality of the 
dipstick. 
If the specimen is dipstick POSITIVE
1 Inoculate the first 10 positive specimens 
at each individual facility into Cary-Blair 
transport media to be sent for culture. 
To do so:
1 Dip cotton-tipped wooden stick into 
the fresh stool/specimen-enriched 
APW and then stab stick into Cary-
Blair transport tube. Cotton tip 
should be inserted to the bottom of 
the Cary Blair media.
2 Break off the tip of the cotton-tipped 
wooden stick and close the tube 
tightly.
If transport media is not available 
1 Blot stool directly onto a Filter Paper 
card (shown at the right) , filling one 
circle and labeling with patient id, 
hospital name, and date. (for further 
molecular studies)
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ANNEX 3: Vaccination Talley Sheet
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ANNEX 4: OCV Adverse Event Following Immunization (AEFI) Reporting Form
Date of report:
                                                                     Age:                   M /F: 
> 3 years old: yes/no        Pregnant: yes/no        Immune compromised: yes/no
District:                                   Village:                            Ward:
  Vaccination target areas 
Dates of vaccines                           First:             Second:









Yes / No | 
Yes / No | 
Yes / No | 
Yes / No | 
Yes / No |
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ANNEX 5: IEC Materials
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ANNEX 6: Example Situation Report
Department of Health Services (DoHS)
Epidemiology and Disease Control Division (EDCD)
HOSPITAL-BASED SURVEILLANCE OF CHOLERA AND ACUTE GASTRO ENTERITIS CASES IN THE 
KATHMANDU VALLEY - DAILY SITUATION UPDATE1
Date: as of 28 July 2016
Key points and interventions
l(24 cholera cases were confirmed by the National Public Health Laboratory so far since 30 June, 
6 cases in Kathmandu and 18 cases in Lalitpur,
l(Four additional cases were diagnosed in Patan hospital,
l(WASH and social mobilization activities are taking place in wards 10, 11 and 12 in Thaiba, 
including door-to-door visit, distribution of PIYUSH, awareness messages.
Table 1: Number of Acute Gastro Enteritis (AGE) and cholera cases reported, by hospital (excludes 
zero reporting)
Hospitals Number of Acute 
Watery Diarrhoea
Number of probable 
cholera cases2












STIDTeku, Kathmandu 224 3 3
Kanti Children Hospital, Kathmandu 35 1 1
Kathmandu Medical College, 
Kathmandu
77
Nepal Medical College, Kathmandu 52
Birendra Army Hospital, Kathmandu 33
Central Prison Hospital, Kathmandu 2
Patan Hospital, Lalitpur 6 141 4 22 3 18
KIST Medical College, Lalitpur 73 2 2
Bhaktapur Hospital 121
Sidhi Memorial Hospital, Bhaktapur
Dulikhel Hospital
Total 6 758 28 24
1 The cases reported here include the new cases registered in the hospitals during the last 24 hours.
2 Number of cholera cases confirmed by hospitals using Dipstick Rapid Diagnostic Tests or culture confirmed (TCBS and cholera-specific 
biochemical confirmation).
3 Number of cholera cases confirmed by NPHL, including serology.Please note that the WHO and EWARS case definitions includes 
children above 5 years, but one year age cut-off is used for the purpose of this active surveillance system.
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Figure 1: Number of Acute Gastro-Enteritis cases, probable and confirmed cholera cases 
(N=22) reported to EDCD as of 28 July 2016 
Acute Watery Diarrhoea is not necessarily reported daily by all hospitals and the decreasing 
trend observed after 8 July can be explained by under-reporting. Cholera cases are still sporadic 
and are expected in this season.
Figure 2: Distribution of cholera and acute watery diarrhoea in the Kathmandu Valley
National Preparedness and Response Plan for Acute Gastroenteritis/ Cholera Outbreaks in Nepal38
Table 2: Number of cholera cases reported by area as of 28 July
District Area Week 30 Week 29 Week 28 Previous Total




Jadibuti (Koteshwor) 1 1







Harisiddhi 3 1 4
Thaiba/Godawari 1 1 2 1 5
Total 4 10 10 4 28
Acknowledgments: this bulletin is prepared by the CTI network, including expert focal points 
from 11 hospitals of the Kathmandu Valley reporting to EDCD and NPHL and supported 
by UNICEF, the World Health Organization, Johns Hopkins University, and The Group For 
Technical Assistance.
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ANNEX 7b: Variable Definitions










Hospital Admitted Yes Y
No N









Primary Source Piped water; piped into dwellling; piped to yard Piped Water
Public tap/standpipe Public Tap
Tube well or borehole; dug well; protected well; 
unprotected well
Tube Well
Water from spring; protected spring; unprotected 
spring
Spring Water
Rain water Rain Water
Tanker truck Tanker
Surface water(river/dam); lake; pond; stream; canal Surface Water
Irrigation channel Irrigation Channel
Stone tap/dhara Stone Tap
Bottled water Bottled Water
Jar water Jar Water
Others Others
Secondary Source Piped water; piped into dwelling; piped to yard Piped Water
Public tap/standpipe Public Tap
Tube well or borehole; dug well; protected well; 
unprotected well
Tube Well
Water from spring; protected spring; unprotected 
spring
Spring Water
Rain water Rain Water
Tanker truck Tanker
Surface water(river/dam); lake; pond; stream; canal Surface Water
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Variable Name Definition Code
Irrigation channel Irrigation Channel
Stone tap/dhara Stone Tap
Bottled water Bottled Water







Add piyush/water guard Piyush/Water Guard
Strain through a cloth Cloth Filter
Use water filter (ceramic/biosand/colloidal filter) Ceramic Filter
Solar disinfection SoDis
Letting stand and settle Stand and Settle
None None
Others Others
Storage Changed Recently Yes Y
No N
Hand Washing Yes Y
No N
Toilet Flush or pour flush toilet Flush Toilet
Water seal latrine Water Seal Latrine
Pit latrine Pit Latrine
Ventilated improved pit latrine VIP Latrine
Pit latrine with slab Slab Pit Latrine
Pit latrine without slab/open pit Open Pit
Composing toilet Composing Toilet
Bucket toilet Bucket Toilet
No facility/bush/field None
Others Others
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ANNEX 8: M&E Indicators
Components Indicator Numerator Denominator Means of verification











Routine monitoring of 
water quality (expected 
monthly)
Number of reports 
by DWSS to the 
Task Force for 
Cholera Control
Total number 
of Task Force 
meetings
DWSS water quality 











Daily / Weekly line 
listings
Timeliness of 
reporting cases to 
the EWARS system 
Average time from hospital 
admission to EWARS reporting
Daily / Weekly line 
listings Hospital 
records
Timely distribution of 
situation reports during 
non-outbreak (expected 
weekly)
Number of weekly 
report distributed 
on time




Timely distribution of 
situation reports during 
outbreak (expected 
daily)







Response Number of reported 
cholera cases that are 
investigated





Presence of all 
required RRT members 
on investigations
Number of days 
with all RRT 
members present
Total number 




Number of meetings 
held by Task Force 

















a shortage of 
WASH resources
Total number of 
districts
Stock Book, LMIS 
Report
Adequate availability of 




a shortage of IEC/
BCC resources
Total number of 
districts
Stock Book, LMIS 
Report
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Components Indicator Numerator Denominator Means of verification
Response Adequate availability of 
vaccine
Number of 
cholera cases for 
which vaccine 
was not available
Total number of 
cholera cases
Stock Book, LMIS 
Report 






Total number of 
cholera cases
Risk Factor Forms           
Situation Reports
Need for contingency 
stocks
Number of requests for additional 
supplies
NPHL Stock Book, 
LMIS Report




Total number of 
districts
DoHS Annual Report 
Laboratory Timeliness of reporting 
lab results to the 
EWARS system 
Average time from the sample 
being sent to NPHL to                                                     
EWARS reporting the case as 
confirmed
NPHL registers                              
Situation reports
Number of samples 





Total number of 
samples sent to 
NPHL 
NPHL registers
 Number of samples 






of samples sent 
























of sentinel site 
hospitals
NPHL Stock Book 
Adequate availability 












of lab supplies at the 
national lab
Number of requests from NPHL for 
additional supplies
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